

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

**CUMULATIVE
SUPPLEMENT 04**
April 2007



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

27th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2007

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

27th EDITION

Cumulative Supplement 04

April 2007

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	iv
1.5 Report of Counts for the Prescription Drug Product List	iv
1.6 Cumulative Supplement Legend	v
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

27th EDITION

**CUMULATIVE SUPPLEMENT 04
April 2007**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 27th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 26th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 27th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BERLEX INC (BERLEX)	BAYER HEALTHCARE PHARMACEUTICALS INC (BAYER HLTHC)
BIONICHE PHARMA (BIONICHE PHARMA)	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)
BIONICHE PHARMA (CANADA) LTD (BIONICHE (CANADA))	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)
BIONICHE PHARMA USA INC (BIONICHE PHARM USA)	BIONICHE PHARMA USA LLC (BIONICHE PHARMA)
MAYNE PHARMA USA INC (MAYNE PHARMA USA)	HOSPIRA INC (HOSPIRA)
QLT USA INC (QLT USA)	TOLMAR INC (TOLMAR)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://www.bookstore.gpo.gov/>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2006</u>	<u>MAR 2007</u>	<u>JUN 2007</u>	<u>SEPT 2007</u>
DRUG PRODUCTS LISTED	11896	12063		
SINGLE SOURCE	2471	2471		
	(20.8%)	(20.5%)		
MULTISOURCE	9336	9503		
	(78.5%)	(78.8%)		
THERAPEUTICALLY	9139	9320		
EQUIVALENT	(76.8%)	(77.3%)		
NOT THERAPEUTICALLY	197	183		
EQUIVALENT	(1.7%)	(1.5%)		
EXCEPTIONS ¹	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES				
APPROVED	10	4		
NUMBER OF APPLICANTS	666	675		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month.

The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>.

All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 27TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2007

1-1

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

@ SPECIALITY EUROPEAN 100MG/VIAL N21320 001 Nov 25, 2003 Feb CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA BOCA PHARMA 356.4MG;30MG;16MG N40688 001 Apr 03, 2007 Mar NEWA
 AA + MIKART 356.4MG;30MG;16MG N40109 001 Aug 26, 1997 Mar CTEC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA BOCA PHARMA 712.8MG;60MG;32MG N40701 001 Apr 03, 2007 Mar NEWA
 AA + MIKART 712.8MG;60MG;32MG N40316 001 Apr 28, 1999 Feb CTEC
 AA WEST WARD 712.8MG;60MG;32MG N40637 001 Sep 22, 2006 Feb CTEC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA INTERPHARM 500MG;10MG N40813 001 Feb 23, 2007 Feb NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB WOCKHARDT 325MG;50MG N77677 001 Mar 16, 2007 Mar NEWA
 AB 650MG;100MG N77677 002 Mar 16, 2007 Mar NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

+ ARMSTRONG PHARMS 0.09MG/INH N72273 001 Aug 14, 1996 Mar CRLD
 @ IVAX PHARMS 0.09MG/INH N73272 001 Dec 28, 1995 Mar DISC
 VENTOLIN
 @ GLAXOSMITHKLINE 0.09MG/INH N18473 001 Mar DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN APOTEX INC EQ 0.083% BASE N75717 001 Feb 02, 2007 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB MYLAN EQ 4MG BASE N78092 002 Jan 29, 2007 Jan NEWA
 AB EQ 8MG BASE N78092 001 Jan 29, 2007 Jan NEWA
 VOSPIRE ER
 AB DAVA PHARMS INC EQ 4MG BASE N76130 002 Sep 26, 2002 Jan CTEC
 AB + EQ 8MG BASE N76130 003 Sep 26, 2002 Jan CTEC

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

>D> + MERCK EQ 70MG BASE;2,800 IU N21762 001 Apr 07, 2005 Apr CRLD
 >A> EQ 70MG BASE;2,800 IU N21762 001 Apr 07, 2005 Apr CRLD
 >A> + EQ 70MG BASE;5,600 IU N21762 002 Apr 26, 2007 Apr NEWA

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

	NOVARTIS	EQ 150MG BASE	N21985 001	Mar 05, 2007	Mar	NEWA
+		EQ 300MG BASE	N21985 002	Mar 05, 2007	Mar	NEWA

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	APOTEX INC	0.25MG	N77741 001	Jan 19, 2007	Jan	NEWA
AB		0.5MG	N77741 002	Jan 19, 2007	Jan	NEWA
AB		1MG	N77741 003	Jan 19, 2007	Jan	NEWA
AB		2MG	N77741 004	Jan 19, 2007	Jan	NEWA
AB	DAVA INTL INC	0.25MG	N74174 001	Oct 19, 1993	Mar	CMFD
	@	0.25MG	N74174 001	Oct 19, 1993	Feb	CAHN
AB		0.5MG	N74174 002	Oct 19, 1993	Mar	CMFD
	@	0.5MG	N74174 002	Oct 19, 1993	Feb	CAHN
AB		1MG	N74174 003	Oct 19, 1993	Mar	CMFD
	@	1MG	N74174 003	Oct 19, 1993	Feb	CAHN
AB		2MG	N74174 004	Oct 19, 1993	Mar	CMFD
	@	2MG	N74174 004	Oct 19, 1993	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.5MG	N78056 001	Feb 13, 2007	Jan	NEWA
AB		1MG	N78056 002	Feb 13, 2007	Jan	NEWA
AB		2MG	N78056 003	Feb 13, 2007	Jan	NEWA
AB		3MG	N78056 004	Feb 13, 2007	Jan	NEWA
AB	COREPHARMA	0.5MG	N77996 001	Jan 31, 2007	Jan	NEWA
AB		1MG	N77996 002	Jan 31, 2007	Jan	NEWA
AB		2MG	N77996 003	Jan 31, 2007	Jan	NEWA
AB		3MG	N77996 004	Jan 31, 2007	Jan	NEWA
AB	TEVA PHARMS	0.5MG	N77979 001	Feb 28, 2007	Feb	NEWA
AB		1MG	N77979 002	Feb 28, 2007	Feb	NEWA
AB		2MG	N77979 003	Feb 28, 2007	Feb	NEWA
AB		3MG	N77979 004	Feb 28, 2007	Feb	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

+	SCHWARZ PHARMA	1MG	N21726 003	Jan 19, 2005	Jan	CRLD
		2MG	N21726 004	Jan 19, 2005	Jan	CRLD

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

>D>						
>D>	PHARMACIA AND UPJOHN	0.01MG/VIAL	N21212 001	Jun 11, 2002	Apr	CTNA
>D>		0.02MG/VIAL	N21212 002	Jun 11, 2002	Apr	CTNA
>A>	CAVERJECT IMPULSE					
>A>	PHARMACIA AND UPJOHN	0.01MG/VIAL	N21212 001	Jun 11, 2002	Apr	CTNA
>A>		0.02MG/VIAL	N21212 002	Jun 11, 2002	Apr	CTNA

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 11.4%

+	HOSPIRA	11.4% (11.4GM/100ML)	N17957 003	Aug 09, 1982	Jan	CRLD
	NOVAMINE 15%					
+	HOSPIRA	15% (15GM/100ML)	N17957 004	Nov 28, 1986	Jan	CRLD

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	HIKMA PHARMS	250MG	N65291 001	Feb 05, 2007	Jan	NEWA
AB		500MG	N65291 002	Feb 05, 2007	Jan	NEWA

FOR SUSPENSION; ORAL

AMOXICILLIN

AB	SANDOZ	125MG/5ML	N65387 001	Mar 26, 2007	Mar	NEWA
AB		200MG/5ML	N65378 001	Mar 26, 2007	Mar	NEWA
AB		250MG/5ML	N65387 002	Mar 26, 2007	Mar	NEWA
AB		400MG/5ML	N65378 002	Mar 26, 2007	Mar	NEWA

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

AB	AUROBINDO PHARMA	200MG	N65324 001	Jan 17, 2007	Jan	NEWA
AB		400MG	N65324 002	Jan 17, 2007	Jan	NEWA
	DISPERMOX					
AB	RANBAXY	200MG	N65080 002	Aug 11, 2003	Jan	CTEC
AB	+	400MG	N65080 001	Aug 11, 2003	Jan	CTEC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	RANBAXY	600MG/5ML;EQ 42.9MG BASE/5ML	N65207 002	Jan 30, 2007	Jan	NEWA
	AUGMENTIN ES-600					
AB	+	SMITHKLINE BEECHAM 600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	Jun 22, 2001	Mar	CAHN

ARIPIPIRAZOLE

SOLUTION; ORAL

ABILIFY

>D>	+	OTSUKA	1MG/ML	N21713 001	Dec 10, 2004	Apr	CAHN
>A>	+	OTSUKA PHARM	1MG/ML	N21713 001	Dec 10, 2004	Apr	CAHN

TABLET; ORAL

ABILIFY

		OTSUKA	15MG	N21436 002	Nov 15, 2002	Feb	CRLD
			30MG	N21436 004	Nov 15, 2002	Feb	CRLD

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

	+	OTSUKA	10MG	N21729 002	Jun 07, 2006	Feb	CRLD
			30MG	N21729 005	Jun 07, 2006	Feb	CRLD

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC

AB	GRACEWAY	385MG;30MG;25MG	N13416 003	Oct 27, 1982	Jan	CAHN
	NORGESIC FORTE					
AB	+	GRACEWAY 770MG;60MG;50MG	N13416 004	Oct 27, 1982	Jan	CAHN

AZATHIOPRINE

TABLET; ORAL

AZATHIOPRINE

AB	ZYDUS PHARMS USA	50MG	N77621 001	Mar 15, 2007	Mar	NEWA
----	------------------	------	------------	--------------	-----	------

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

AP	PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	N65265 001	Jan 18, 2007	Jan	NEWA
>A>	SOLUTION/DROPS; OPHTHALMIC					
>A>	AZASITE					
>A>	+ INSITE VISION	1%	N50810 001	Apr 27, 2007	Apr	NEWA

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

	@ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416 002		Feb	DISC
	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE					
	+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068 001	Oct 30, 1995	Feb	CTEC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOSPORIN

	@ MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417 001		Feb	DISC
--	------------------	--	------------	--	-----	------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

POLYSPORIN

	@ MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229 001		Feb	DISC
--	------------------	------------------------------	------------	--	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

	+ IVAX RES	0.04MG/INH	N20911 002	Sep 15, 2000	Mar	CAHN
--	------------	------------	------------	--------------	-----	------

QVAR 80

	+ IVAX RES	0.08MG/INH	N20911 001	Sep 15, 2000	Mar	CAHN
--	------------	------------	------------	--------------	-----	------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

AB	KING PHARMS	5MG;40MG	N18647 001	May 25, 1983	Mar	CFTG
----	-------------	----------	------------	--------------	-----	------

AB	+	5MG;80MG	N18647 002	May 25, 1983	Mar	CFTG
----	---	----------	------------	--------------	-----	------

NADOLOL AND BENDROFLUMETHIAZIDE

AB	IMPAX LABS	5MG;40MG	N77833 001	Mar 30, 2007	Mar	NEWA
----	------------	----------	------------	--------------	-----	------

AB		5MG;80MG	N77833 002	Mar 30, 2007	Mar	NEWA
----	--	----------	------------	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	THE PHARMA NETWORK	100MG	N40627 001	Mar 30, 2007	Mar	NEWA
----	--------------------	-------	------------	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

>A>	@ SANOFI AVENTIS US	5%;EQ 1% BASE	N50756 002	Apr 20, 2007	Apr	DISC
-----	---------------------	---------------	------------	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	TEDOR PHARM	50MG	N40747 001	Mar 30, 2007	Mar	NEWA
>A>	AA	TYCO HLTHCARE	N40773 001	Apr 25, 2007	Apr	NEWA

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

>D>	+	JAZZ	1GM/SCOOPFUL	N20576 001	Oct 25, 1996	Apr	CAHN
>A>	+	RARE DIS	1GM/SCOOPFUL	N20576 001	Oct 25, 1996	Apr	CAHN

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

ASTRAZENECA 0.08MG/INH

N21949 001 Jul 12, 2006 Feb CTNA

+ 0.16MG/INH

N21949 002 Jul 12, 2006 Feb CTNA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

SPRAY, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH;0.045MG/INH

N21929 001 Jul 21, 2006 Jan CAIN

+ 0.16MG/INH;0.045MG/INH

N21929 002 Jul 21, 2006 Jan CAIN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP	PHARMAFORCE	EQ 0.3MG BASE/ML	N78331 001	Mar 27, 2007	Mar	NEWA
----	-------------	------------------	------------	--------------	-----	------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	IVAX PHARMS INC	0.5MG	N77750 001	Mar 07, 2007	Feb	NEWA
----	-----------------	-------	------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 50

>D>		ORION PHARMA INC	12.5MG;200MG;50MG	N21485 001	Jun 11, 2003	Apr	CRLD
-----	--	------------------	-------------------	------------	--------------	-----	------

>A>	+		12.5MG;200MG;50MG	N21485 001	Jun 11, 2003	Apr	CRLD
-----	---	--	-------------------	------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	AP	GENERAMEDIX	EQ 50MG/5ML (10MG/ML)	N77998 001	Apr 24, 2007	Apr	NEWA
>A>	AP		EQ 150MG/ML (10MG/ML)	N77998 002	Apr 24, 2007	Apr	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N77998 003	Apr 24, 2007	Apr	NEWA
	AP	SICOR PHARMS	EQ 50MG/5ML (10MG/ML)	N77389 001	Mar 30, 2007	Mar	NEWA
	AP		EQ 150MG/15ML (10MG/ML)	N77389 002	Mar 30, 2007	Mar	NEWA
	AP		EQ 450MG/45ML (10MG/ML)	N77389 003	Mar 30, 2007	Mar	NEWA
	AP	WATSON LABS	EQ 50MG/5ML (10MG/ML)	N77861 001	Jan 18, 2007	Jan	NEWA
	AP		EQ 150MG/15ML (10MG/ML)	N77861 002	Jan 18, 2007	Jan	NEWA
	AP		EQ 450MG/45ML (10MG/ML)	N77861 003	Jan 18, 2007	Jan	NEWA
	AP		EQ 600MG/60ML (10MG/ML)	N77861 004	Jan 18, 2007	Jan	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA SUN PHARM INDS LTD 350MG N40755 001 Feb 27, 2007 Feb NEWA

CEFACLOR

CAPSULE; ORAL
CEFACLOR

>D> AB CEPH INTL EQ 250MG BASE N62205 001 Apr DISC
>A> @ EQ 250MG BASE N62205 001 Apr DISC
>D> AB EQ 500MG BASE N62205 002 Apr DISC
>A> @ EQ 500MG BASE N62205 002 Apr DISC
AB HIKMA EQ 250MG BASE N65350 001 Apr 03, 2007 Mar NEWA
AB EQ 500MG BASE N65350 002 Apr 03, 2007 Mar NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB AUROBINDO PHARMA 500MG N65352 001 Jan 25, 2007 Jan NEWA

CEFDINIR

CAPSULE; ORAL
CEFDINIR

AB SANDOZ 300MG N65330 001 Apr 06, 2007 Mar NEWA

FOR SUSPENSION; ORAL

CEFDINIR

>A> AB LUPIN 250MG/5ML N65259 002 May 07, 2007 Apr NEWA
AB SANDOZ 125MG/5ML N65337 001 Apr 06, 2007 Mar NEWA
AB 250MG/5ML N65337 002 Apr 06, 2007 Mar NEWA
>A> AB TEVA PHARMS 125MG/5ML N65332 001 May 04, 2007 Apr NEWA
>A> AB 250MG/5ML N65332 002 May 04, 2007 Apr NEWA
OMNICEF
AB + ABBOTT 250MG/5ML N50749 002 Jul 29, 2004 Mar CFTG

CEFIXIME

SUSPENSION; ORAL
CEFIXIME

>D> LUPIN PHARMS 200MG/5ML N65355 001 Apr 10, 2007 Apr CRLD
200MG/5ML N65355 001 Apr 10, 2007 Mar NEWA
SUPRAX
>D> + LUPIN 100MG/5ML N65129 001 Feb 23, 2004 Apr CRLD
>A> LUPIN PHARMS 100MG/5ML N65129 001 Feb 23, 2004 Apr CRLD
>A> + 200MG/5ML N65355 001 Apr 10, 2007 Apr CRLD

CEFPROZIL

FOR SUSPENSION; ORAL
CEFPROZIL

AB AUROBINDO PHARMA 125MG/5ML N65381 001 Jan 30, 2007 Jan NEWA
AB 250MG/5ML N65381 002 Jan 30, 2007 Jan NEWA

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX

@ ASTELLAS

EQ 1GM BASE/VIAL

N50560 002 Sep 15, 1983 Feb DISC

INJECTABLE; INJECTION

CEFIZOX

+	ASTELLAS	EQ 1GM BASE/VIAL	N63294 002	Mar 31, 1994	Feb	CRLD
---	----------	------------------	------------	--------------	-----	------

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	N65294 001	Mar 26, 2007	Mar	NEWA
AP		EQ 500MG BASE/VIAL	N65294 002	Mar 26, 2007	Mar	NEWA
AP		EQ 1GM BASE/VIAL	N65294 003	Mar 26, 2007	Mar	NEWA
AP		EQ 2GM BASE/VIAL	N65294 004	Mar 26, 2007	Mar	NEWA
AP	HANFORD GC	EQ 1GM BASE/VIAL	N65268 001	Feb 28, 2007	Feb	NEWA
AP		EQ 2GM BASE/VIAL	N65268 002	Feb 28, 2007	Feb	NEWA
AP	SICOR PHARMS	EQ 250MG BASE/VIAL	N65227 001	Mar 15, 2007	Mar	NEWA
AP		EQ 500MG BASE/VIAL	N65227 002	Mar 15, 2007	Mar	NEWA
AP		EQ 1GM BASE/VIAL	N65227 003	Mar 15, 2007	Mar	NEWA
AP		EQ 2GM BASE/VIAL	N65227 004	Mar 15, 2007	Mar	NEWA
>A>	TEVA	EQ 1GM BASE/VIAL	N65262 001	Jun 29, 2006	Apr	CTNA
>A>		EQ 2GM BASE/VIAL	N65262 002	Jun 29, 2006	Apr	CTNA
>A>	WOCKHARDT	EQ 250MG BASE/VIAL	N65391 001	Apr 12, 2007	Apr	NEWA
>A>		EQ 500MG BASE/VIAL	N65391 002	Apr 12, 2007	Apr	NEWA
>A>		EQ 2GM BASE/VIAL	N65391 003	Apr 12, 2007	Apr	NEWA
>D>	CEFTRIAZONE SODIUM					
>D>	TEVA	EQ 1GM BASE/VIAL	N65262 001	Jun 29, 2006	Apr	CTNA
>D>		EQ 2GM BASE/VIAL	N65262 002	Jun 29, 2006	Apr	CTNA

INJECTABLE; INJECTION

CEFTRIAZONE

AP	HANFORD GC	EQ 10GM BASE/VIAL	N65269 001	Feb 28, 2007	Feb	NEWA
----	------------	-------------------	------------	--------------	-----	------

CELECOXIB

CAPSULE; ORAL

CELEBREX

GD SEARLE	50MG	N20998 004	Dec 15, 2006	Jan	NEWA
-----------	------	------------	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+	ABRAXIS PHARM	EQ 1GM BASE/VIAL	N62365 001	Aug 25, 1982	Feb	CRLD
---	---------------	------------------	------------	--------------	-----	------

CHLOROMYCETIN

@	PARKEDEALE	EQ 1GM BASE/VIAL	N50155 001		Feb	DISC
---	------------	------------------	------------	--	-----	------

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+	SALIX PHARMS	250MG/5ML	N11870 001		Feb	CAHN
---	--------------	-----------	------------	--	-----	------

CHLORPHENIRAMINE POLYSTIREX; CODEINE POLYSTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

@	UCB INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369 001	Jun 21, 2004	Mar	DISC
---	---------	--	------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN

>A>	AB	AUROBINDO PHARMA	EQ 250MG BASE	N77859 001	Apr 26, 2007	Apr	NEWA
-----	----	------------------	---------------	------------	--------------	-----	------

TABLET; ORAL

CIPROFLOXACIN

>A>	AB	AUROBINDO PHARMA	EQ 500MG BASE	N77859 002	Apr 26, 2007	Apr	NEWA
>A>	AB		EQ 750MG BASE	N77859 003	Apr 26, 2007	Apr	NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

AB	+	BAYER PHARMS	212.6MG;EQ 287.5MG BASE	N21473 001	Dec 13, 2002	Mar	CFTG
AB	+		425.2MG;EQ 574.9MG BASE	N21473 002	Aug 28, 2003	Mar	CFTG

CIPROFLOXACIN EXTENDED RELEASE

AB		DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	N77701 001	Mar 26, 2007	Mar	NEWA
AB		MYLAN	212.6MG;EQ 287.5MG BASE	N78183 001	Mar 22, 2007	Mar	NEWA
AB			425.2MG;EQ 574.9MG BASE	N78183 002	Mar 22, 2007	Mar	NEWA

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

@	BEDFORD	10MG/VIAL	N74713 001	Nov 14, 2000	Mar	DISC
@		50MG/VIAL	N74713 002	Nov 14, 2000	Mar	DISC

PLATINOL

+	BRISTOL MYERS	10MG/VIAL	N18057 001		Mar	CTEC
+		50MG/VIAL	N18057 002		Mar	CTEC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	ALPHAPHARM	EQ 10MG BASE	N77668 001	Feb 28, 2007	Feb	NEWA
		EQ 20MG BASE	N77668 002	Feb 28, 2007	Feb	NEWA
+		EQ 40MG BASE	N77668 003	Feb 28, 2007	Feb	NEWA

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB		TORRENT PHARMS	EQ 10MG BASE	N78216 001	Mar 27, 2007	Mar	NEWA
AB			EQ 20MG BASE	N78216 002	Mar 27, 2007	Mar	NEWA
AB			EQ 40MG BASE	N78216 003	Mar 27, 2007	Mar	NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP		ABRAXIS PHARM	EQ 150MG BASE/ML	N65346 001	Mar 29, 2007	Mar	NEWA
----	--	---------------	------------------	------------	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX E

+	CONNETICS	0.05%	N22013 001	Jan 12, 2007	Jan	NEWA
---	-----------	-------	------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT		ALTANA	0.05%	N75391 001	Feb 08, 1999	Feb	CMFD
----	--	--------	-------	------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB		VINTAGE	0.1MG	N77901 001	Mar 09, 2007	Feb	NEWA
AB			0.2MG	N77901 002	Mar 09, 2007	Feb	NEWA
AB			0.3MG	N77901 003	Mar 09, 2007	Feb	NEWA

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

>D>	@ PHARMACIA AND UPJOHN	25MG/ML	N08126 002		Apr	DISC
>A>	@	25MG/ML	N08126 002		Apr	DISC

TABLET; ORAL

CORTISONE ACETATE

>D>	PHARMACIA AND UPJOHN	5MG	N08126 003		Apr	DISC
>A>	@	5MG	N08126 003		Apr	DISC
>D>		10MG	N08126 004		Apr	DISC
>A>	@	10MG	N08126 004		Apr	DISC
>D>	BP +	25MG	N08126 001		Apr	DISC
>A>	@	25MG	N08126 001		Apr	DISC
>D>	BP WEST WARD	25MG	N80776 002		Apr	CRLD
>A>	+	25MG	N80776 002		Apr	CRLD

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

	ECR	15MG	N21777 001	Feb 01, 2007	Feb	NEWA
	+	30MG	N21777 002	Feb 01, 2007	Feb	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	VINTAGE PHARMS	5MG	N77797 001	Feb 28, 2007	Feb	NEWA
AB		10MG	N77797 002	Feb 28, 2007	Feb	NEWA

DANAZOL

CAPSULE; ORAL

DANAZOL

>D>	BARR	50MG	N74582 003	May 29, 1998	Apr	CTEC
>A>	AB	50MG	N74582 003	May 29, 1998	Apr	CTEC
>D>		100MG	N74582 002	May 29, 1998	Apr	CTEC
>A>	AB	100MG	N74582 002	May 29, 1998	Apr	CTEC
>A>	AB LANNETT	50MG	N78214 001	Apr 19, 2007	Apr	NEWA
>A>	AB	100MG	N78214 002	Apr 19, 2007	Apr	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

	@ STIEFEL	75MG	N50261 001		Mar	CAHN
AB		150MG	N50261 002		Mar	CAHN
AB	+	300MG	N50261 003		Mar	CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	10MG	N74430 001	Feb 09, 1996	Mar	CAHN
AB		25MG	N71601 001	Jun 05, 1987	Mar	CAHN
AB		75MG	N71602 001	Oct 05, 1987	Mar	CAHN
AB		100MG	N71766 001	Oct 05, 1987	Mar	CAHN
AB		150MG	N74430 002	Feb 09, 1996	Mar	CAHN
AB	AMIDE PHARM	50MG	N71588 001	Jun 05, 1987	Mar	CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

>A>	+	CSL BEHRING	0.15MG/SPRAY	N20355 001	Mar 07, 1994	Apr	CAHN
>D>	+	ZLB BEHRING	0.15MG/SPRAY	N20355 001	Mar 07, 1994	Apr	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		TEVA PHARMS	2.5MG	N77107 003	Jan 29, 2007	Jan	NEWA
AB			5MG	N77107 001	Jan 29, 2007	Jan	NEWA
AB			10MG	N77107 002	Jan 29, 2007	Jan	NEWA
		FOCALIN					
AB		NOVARTIS	2.5MG	N21278 001	Nov 13, 2001	Jan	CFTG
AB			5MG	N21278 002	Nov 13, 2001	Jan	CFTG
AB	+		10MG	N21278 003	Nov 13, 2001	Jan	CFTG

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXEDRINE

@ GLAXOSMITHKLINE 5MG

N84935 001 Feb DISC

DEXTROSTAT

AA	+	SHIRE	5MG	N84051 001		Mar	CAHN
AA	+		10MG	N84051 002		Mar	CAHN

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+ INST BIOCHEM 1.3%

N21234 001 Jan 31, 2007 Jan NEWA

DIDANOSINE

FOR SOLUTION; ORAL

DIDANOSINE

AA		AUROBINDO PHARMA	10MG/ML	N78112 001	Mar 08, 2007	Feb	NEWA
----	--	------------------	---------	------------	--------------	-----	------

VIDEX

AA	+	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	Oct 09, 1991	Feb	CFTG
----	---	----------------------	---------	------------	--------------	-----	------

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

@ IMCOR PHARMS CO 0.92MG/VIAL;0.092MG/VIAL

N21191 001 May 31, 2002 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

@ MCNEIL CONS 10MG/ML

N06146 001 Mar CAHN

AP	+		50MG/ML	N06146 002		Mar	CAHN
----	---	--	---------	------------	--	-----	------

BENADRYL PRESERVATIVE FREE

AP	+	MCNEIL CONS	50MG/ML	N09486 001		Mar	CAHN
----	---	-------------	---------	------------	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		MURTY PHARMS	25MG	N40733 001	Feb 13, 2007	Jan	NEWA
----	--	--------------	------	------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

AB	MURTY PHARMS	50MG	N40733 002	Feb 13, 2007	Jan	NEWA
AB		75MG	N40733 003	Feb 13, 2007	Jan	NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

>D>	AP	BEDFORD	10MG/VIAL	N62921 001	Mar 17, 1989	Apr	CRLD
>A>	AP	+	10MG/VIAL	N62921 001	Mar 17, 1989	Apr	CRLD
>D>	AP		20MG/VIAL	N62921 002	Mar 17, 1989	Apr	CRLD
>A>	AP	+	20MG/VIAL	N62921 002	Mar 17, 1989	Apr	CRLD
>D>	AP		50MG/VIAL	N62921 003	Mar 17, 1989	Apr	CRLD
>A>	AP	+	50MG/VIAL	N62921 003	Mar 17, 1989	Apr	CRLD
		RUBEX					
		@ BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001	Apr 13, 1989	Mar	DISC
		@	50MG/VIAL	N62926 002	Apr 13, 1989	Mar	DISC
		@	100MG/VIAL	N62926 003	Apr 13, 1989	Mar	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	RANBAXY	EQ 75MG BASE	N65053 003	Sep 10, 2003	Jan	CTEC
AB	MONODOX					
AB	OCLASSEN	EQ 75MG BASE	N50641 003	Oct 18, 2006	Jan	NEWA

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+	GRACEWAY	200MG/ML	N08922 001		Jan	CAHN
---	----------	----------	------------	--	-----	------

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

@	GRACEWAY	500MG	N08922 002		Jan	CAHN
---	----------	-------	------------	--	-----	------

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	+	BEDFORD	1.25MG/ML	N75634 001	Aug 22, 2000	Mar	CRLD
		VASOTEC					
		@ BIOVAIL LABS INTL	1.25MG/ML	N19309 001	Feb 09, 1988	Mar	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

>D>	+	PFIZER INC	2MG/ML	N50778 001	Sep 15, 1999	Apr	CFTG
>A>	AP	+	2MG/ML (200MG/100ML)	N50778 001	Sep 15, 1999	Apr	CFTG
>A>	AP		2MG/ML (50MG/25ML)	N50778 002	Sep 15, 1999	Apr	CFTG

EPIRUBICIN HYDROCHLORIDE

>A>		HOSPIRA	2MG/ML (10MG/5ML)	N65343 001	Apr 19, 2007	Apr	NEWA
>A>			2MG/ML (150MG/75ML)	N65343 003	Apr 19, 2007	Apr	NEWA
>A>	AP		2MG/ML (200MG/100ML)	N65343 004	Apr 19, 2007	Apr	NEWA
>A>	AP		2MG/ML (50MG/25ML)	N65343 002	Apr 19, 2007	Apr	NEWA

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC 2MG N87693 001 Feb 24, 1983 Jan CAHN

ESTAZOLAM

TABLET; ORAL

>D> PROSOM

>D> AB ABBOTT 1MG N19080 001 Dec 26, 1990 Apr DISC

>A> @ 1MG N19080 001 Dec 26, 1990 Apr DISC

>D> AB + 2MG N19080 002 Dec 26, 1990 Apr DISC

>A> @ 2MG N19080 002 Dec 26, 1990 Apr DISC

ESTRADIOL

GEL, METERED; TRANSDERMAL

ELESTRIN

BX + BRADLEY PHARMS 0.06% N21813 001 Dec 15, 2006 Jan CAHN

TABLET; ORAL

ESTRADIOL

@ HERITAGE PHARMS INC 0.5MG N40275 001 Dec 29, 1998 Feb CAHN

@ 1MG N40275 002 Dec 29, 1998 Feb CAHN

@ 2MG N40275 003 Dec 29, 1998 Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

>A> DURAMED 0.9MG N21443 005 Apr 27, 2007 Apr NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D> AB1 WATSON LABS 0.02MG;0.1MG N76625 001 Nov 18, 2004 Apr CRLD

>A> AB1 + 0.02MG;0.1MG N76625 001 Nov 18, 2004 Apr CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL-28

OVCON-35 FE

+ WARNER CHILCOTT 0.035MG;0.4MG N21490 001 Nov 14, 2003 Jan CTNA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

MICROGESTIN 1.5/30

AB WATSON LABS 0.03MG;1.5MG N75548 002 Jul 30, 2003 Jan NEWA

MICROGESTIN 1/20

AB WATSON LABS 0.02MG;1MG N75647 002 Jul 30, 2003 Jan NEWA

TABLET; ORAL-28

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>D> AB ANDRX PHARMS 0.02MG;1MG N77077 001 May 20, 2005 Apr CAHN

>D> AB 0.03MG;1.5MG N77075 001 Apr 28, 2005 Apr CAHN

>A> AB TEVA PHARMS 0.02MG;1MG N77077 001 May 20, 2005 Apr CAHN

>A> AB 0.03MG;1.5MG N77075 001 Apr 28, 2005 Apr CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

PREVIFEM

>D>	AB	ANDRX PHARMS	0.035MG;0.25MG	N76334 001	Jan 09, 2004	Apr	CAHN
>A>	AB	TEVA PHARMS	0.035MG;0.25MG	N76334 001	Jan 09, 2004	Apr	CAHN
TRI-PREVIFEM							
>D>	AB	ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN
>D>	AB		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN
>D>	AB		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN
>A>	AB	TEVA PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN
>A>	AB		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN
>A>	AB		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335 001	Mar 26, 2004	Apr	CAHN

ETODOLAC

CAPSULE; ORAL

ETODOLAC

>D>	AB	AAIPHARMA LLC	300MG	N74929 001	Jan 30, 1998	Apr	DISC
>A>		@	300MG	N74929 001	Jan 30, 1998	Apr	DISC
>D>	AB	GENPHARM	200MG	N75071 001	Sep 30, 1998	Apr	DISC
>A>		@	200MG	N75071 001	Sep 30, 1998	Apr	DISC
>D>	AB		300MG	N75071 002	Sep 30, 1998	Apr	DISC
>A>		@	300MG	N75071 002	Sep 30, 1998	Apr	DISC
>D>	AB	MYLAN	200MG	N74932 001	May 16, 1997	Apr	DISC
>A>		@	200MG	N74932 001	May 16, 1997	Apr	DISC
>D>	AB		300MG	N74932 002	May 16, 1997	Apr	DISC
>A>		@	300MG	N74932 002	May 16, 1997	Apr	DISC
>D>	AB	SANDOZ	200MG	N74840 001	Aug 29, 1997	Apr	DISC
>A>		@	200MG	N74840 001	Aug 29, 1997	Apr	DISC
>D>	AB		200MG	N74942 001	Sep 30, 1997	Apr	DISC
>A>		@	200MG	N74942 001	Sep 30, 1997	Apr	DISC
>D>	AB		300MG	N74840 002	Aug 29, 1997	Apr	DISC
>A>		@	300MG	N74840 002	Aug 29, 1997	Apr	DISC
>D>	AB		300MG	N74942 002	Sep 30, 1997	Apr	DISC
>A>		@	300MG	N74942 002	Sep 30, 1997	Apr	DISC
>D>	AB	TEVA	200MG	N75126 001	Sep 16, 1999	Apr	DISC
>A>		@	200MG	N75126 001	Sep 16, 1999	Apr	DISC
>D>	AB	WATSON LABS	200MG	N74844 001	Dec 23, 1997	Apr	DISC
>A>		@	200MG	N74844 001	Dec 23, 1997	Apr	DISC
>D>	AB		300MG	N74844 002	Dec 23, 1997	Apr	DISC
>A>		@	300MG	N74844 002	Dec 23, 1997	Apr	DISC

TABLET; ORAL

ETODOLAC

>D>	AB	AAIPHARMA LLC	400MG	N74927 001	Oct 30, 1997	Apr	DISC
>A>		@	400MG	N74927 001	Oct 30, 1997	Apr	DISC
>D>	AB	GENPHARM	400MG	N75012 001	Sep 30, 1998	Apr	DISC
>A>		@	400MG	N75012 001	Sep 30, 1998	Apr	DISC
>D>	AB		500MG	N75012 002	Sep 30, 1998	Apr	DISC
>A>		@	500MG	N75012 002	Sep 30, 1998	Apr	DISC
>D>	AB	IVAX PHARMS	400MG	N74883 001	Feb 28, 1997	Apr	DISC
>A>		@	400MG	N74883 001	Feb 28, 1997	Apr	DISC
>D>	AB		500MG	N74883 002	Nov 20, 1998	Apr	DISC

TABLET; ORAL

ETODOLAC

>A>	@	IVAX PHARMS	500MG	N74883 002	Nov 20, 1998	Apr	DISC
>D>	AB	RANBAXY	400MG	N75226 001	Nov 24, 1998	Apr	DISC
>A>	@		400MG	N75226 001	Nov 24, 1998	Apr	DISC
>D>	AB		500MG	N75226 002	Nov 24, 1998	Apr	DISC
>A>	@		500MG	N75226 002	Nov 24, 1998	Apr	DISC
>D>	AB	SANDOZ	400MG	N74839 001	Jul 11, 1997	Apr	DISC
>A>	@		400MG	N74839 001	Jul 11, 1997	Apr	DISC
>D>	AB		400MG	N74846 001	Feb 28, 1997	Apr	DISC
>A>	@		400MG	N74846 001	Feb 28, 1997	Apr	DISC
>D>	AB	TEVA	400MG	N74847 001	Apr 23, 1999	Apr	DISC
>A>	@		400MG	N74847 001	Apr 23, 1999	Apr	DISC
>D>	AB		500MG	N74847 002	Apr 23, 1999	Apr	DISC
>A>	@		500MG	N74847 002	Apr 23, 1999	Apr	DISC
>D>	AB	WATSON LABS	400MG	N74892 001	Apr 16, 1997	Apr	DISC
>A>	@		400MG	N74892 001	Apr 16, 1997	Apr	DISC
>D>	AB		400MG	N75069 001	Apr 16, 1998	Apr	DISC
>A>	@		400MG	N75069 001	Apr 16, 1998	Apr	DISC
>D>	AB		500MG	N74892 002	Oct 29, 1998	Apr	DISC
>A>	@		500MG	N74892 002	Oct 29, 1998	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

>D>	AB	ANDRX PHARMS	400MG	N75829 001	Nov 30, 2001	Apr	DISC
>A>	@		400MG	N75829 001	Nov 30, 2001	Apr	DISC
>D>	AB		500MG	N75829 002	Nov 30, 2001	Apr	DISC
>A>	@		500MG	N75829 002	Nov 30, 2001	Apr	DISC
>D>	AB	SANDOZ	400MG	N75943 001	Jul 26, 2002	Apr	DISC
>A>	@		400MG	N75943 001	Jul 26, 2002	Apr	DISC
>D>	AB		500MG	N75943 002	Jul 26, 2002	Apr	DISC
>A>	@		500MG	N75943 002	Jul 26, 2002	Apr	DISC
>D>	AB		600MG	N75943 003	Jul 26, 2002	Apr	DISC
>A>	@		600MG	N75943 003	Jul 26, 2002	Apr	DISC

FAMOTIDINE

FOR SUSPENSION; ORAL

PEPCID

+	SALIX PHARMS	40MG/5ML	N19527 001	Feb 02, 1987	Feb	CAHN
---	--------------	----------	------------	--------------	-----	------

FENOFIBRATE

TABLET; ORAL

TRIGLIDE

	SKYEPHARMA AG	50MG	N21350 001	May 07, 2005	Jan	CAHN
BX		160MG	N21350 002	May 07, 2005	Jan	CAHN

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

AP	SICOR PHARMS	EQ 10MG BASE/ML	N77826 001	Mar 07, 2007	Feb	NEWA
----	--------------	-----------------	------------	--------------	-----	------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-12

AB	ALZA	12.5UGM/HR	N19813 005	Feb 04, 2005	Jan	CFTG
----	------	------------	------------	--------------	-----	------

FENTANYL-100

AB	LAVIPHARM LABS	100UGM/HR	N77051 004	Aug 04, 2006	Jan	CTNA
----	----------------	-----------	------------	--------------	-----	------

FILM, EXTENDED RELEASE; TRANSDERMALFENTANYL-100

AB	MYLAN TECHNOLOGIES	100UGM/HR	N76258 004	Jan 28, 2005	Jan	CTNA
----	--------------------	-----------	------------	--------------	-----	------

FENTANYL-12

AB	MYLAN TECHNOLOGIES	12.5UGM/HR	N76258 005	Jan 23, 2007	Jan	NEWA
----	--------------------	------------	------------	--------------	-----	------

FENTANYL-25

AB	LAVIPHARM LABS	25UGM/HR	N77051 001	Aug 04, 2006	Jan	CTNA
----	----------------	----------	------------	--------------	-----	------

AB	MYLAN TECHNOLOGIES	25UGM/HR	N76258 001	Jan 28, 2005	Jan	CTNA
----	--------------------	----------	------------	--------------	-----	------

FENTANYL-50

AB	LAVIPHARM LABS	50UGM/HR	N77051 002	Aug 04, 2006	Jan	CTNA
----	----------------	----------	------------	--------------	-----	------

AB	MYLAN TECHNOLOGIES	50UGM/HR	N76258 002	Jan 28, 2005	Jan	CTNA
----	--------------------	----------	------------	--------------	-----	------

FENTANYL-75

AB	LAVIPHARM LABS	75UGM/HR	N77051 003	Aug 04, 2006	Jan	CTNA
----	----------------	----------	------------	--------------	-----	------

AB	MYLAN TECHNOLOGIES	75UGM/HR	N76258 003	Jan 28, 2005	Jan	CTNA
----	--------------------	----------	------------	--------------	-----	------

FENTANYL CITRATE

TABLET; BUCCAL

FENTORA

CEPHALON

EQ 0.3MG BASE

N21947 006	Mar 02, 2007	Mar	NEWA
------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

>A>	AB	MYLAN	180MG	N77081 001	Apr 16, 2007	Apr	NEWA
-----	----	-------	-------	------------	--------------	-----	------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB	ACTAVIS TOTOWA	5MG	N77914 001	Mar 28, 2007	Mar	NEWA
----	----------------	-----	------------	--------------	-----	------

AB	DR REDDYS LABS LTD	5MG	N76437 001	Feb 28, 2007	Feb	NEWA
----	--------------------	-----	------------	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

AB	GRACEWAY	50MG	N18830 004	Aug 23, 1988	Jan	CAHN
----	----------	------	------------	--------------	-----	------

AB		100MG	N18830 001	Oct 31, 1985	Jan	CAHN
----	--	-------	------------	--------------	-----	------

AB	+	150MG	N18830 003	Jun 03, 1988	Jan	CAHN
----	---	-------	------------	--------------	-----	------

@		200MG	N18830 002	Oct 31, 1985	Jan	CAHN
---	--	-------	------------	--------------	-----	------

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP	MAYNE PHARMA USA	50MG/VIAL	N77790 001	Apr 06, 2007	Mar	NEWA
----	------------------	-----------	------------	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

>D>	AP	+	ABRAXIS PHARM	50MG/ML	N40291 001	Mar 24, 1999	Apr	DISC
-----	----	---	---------------	---------	------------	--------------	-----	------

>A>		@		50MG/ML	N40291 001	Mar 24, 1999	Apr	DISC
-----	--	---	--	---------	------------	--------------	-----	------

>D>	AP	+		50MG/ML	N40379 001	Nov 15, 2000	Apr	DISC
-----	----	---	--	---------	------------	--------------	-----	------

>A>		@		50MG/ML	N40379 001	Nov 15, 2000	Apr	DISC
-----	--	---	--	---------	------------	--------------	-----	------

>A>	AP	+		500MG/10ML (50MG/ML)	N40279 002	Sep 30, 1998	Apr	NEWA
-----	----	---	--	----------------------	------------	--------------	-----	------

>D>	AP	+		50MG/ML	N40279 001	Sep 30, 1998	Apr	CPOT
-----	----	---	--	---------	------------	--------------	-----	------

>A>	AP	+		1GM/20ML (50MG/ML)	N40279 001	Sep 30, 1998	Apr	CPOT
-----	----	---	--	--------------------	------------	--------------	-----	------

>D>	AP	+		50MG/ML	N40278 001	Sep 30, 1998	Apr	CPOT
-----	----	---	--	---------	------------	--------------	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP	+	ABRAXIS PHARM	2.5GM/50ML (50MG/ML)	N40278 001	Sep 30, 1998	Apr	CPOT
>A>	AP	+		5GM/100ML (50MG/ML)	N40278 002	Sep 30, 1998	Apr	NEWA
>A>	AP	+	GENERAMEDIX	500MG/10ML (50MG/ML)	N40743 002	Apr 26, 2007	Apr	NEWA
>A>	AP	+		1GM/20ML (50MG/ML)	N40743 001	Apr 26, 2007	Apr	NEWA
>A>	AP	+		2.5GM/50ML (50MG/ML)	N40798 002	Apr 26, 2007	Apr	NEWA
>A>	AP	+		5GM/100ML (50MG/ML)	N40798 001	Apr 26, 2007	Apr	NEWA
>D>	AP	+	SICOR PHARMS	50MG/ML	N40333 001	Jan 27, 2000	Apr	CPOT
>A>	AP	+		500MG/10ML (50MG/ML)	N40333 001	Jan 27, 2000	Apr	CPOT
>D>	AP	+		50MG/ML	N40334 001	Feb 25, 2000	Apr	CPOT
>A>	AP	+		2.5GM/50ML (50MG/ML)	N40334 001	Feb 25, 2000	Apr	CPOT
>A>	AP	+		5GM/100ML (50MG/ML)	N40334 002	Feb 25, 2000	Apr	NEWA
>D>	AP	+	VALEANT	50MG/ML	N12209 001		Apr	CPOT
>A>	AP	+		500MG/10ML (50MG/ML)	N12209 001		Apr	CPOT

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA			SILARX	EQ 20MG BASE/5ML	N77849 001	Feb 09, 2007	Jan	NEWA
----	--	--	--------	------------------	------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

SYMBYAX

>A>			LILLY	EQ 25MG BASE;EQ 3MG BASE	N21520 001		Apr	NEWA
-----	--	--	-------	--------------------------	------------	--	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO	+		BEDFORD	25MG/ML	N74531 001	Aug 30, 1996	Jan	CRLD
			PROLIXIN DECANOATE					
			@ BRISTOL MYERS SQUIBB	25MG/ML	N16727 001		Jan	DISC

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

	+		ABRAXIS PHARM	2.5MG/ML	N89556 001	Apr 16, 1987	Jan	CRLD
			PROLIXIN					
			@ APOTHECON	2.5MG/ML	N11751 005		Jan	DISC

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	+		MYLAN	10MG	N89804 001	Aug 12, 1988	Feb	CRLD
			PROLIXIN					
			@ APOTHECON	1MG	N11751 004		Jan	DISC
			@	2.5MG	N11751 001		Jan	DISC
			@	5MG	N11751 003		Jan	DISC
			@	10MG	N11751 002		Jan	DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

>A>	AB		THERAGEN	100MG	N74560 002	May 16, 1997	Apr	CAHN
>D>	AB		WARNER CHILCOTT	100MG	N74560 002	May 16, 1997	Apr	CAHN

>A>	<u>FLUTICASONE FUROATE</u>							
>A>	SPRAY, METERED; NASAL							
>A>	VERAMYST							
>A>	+	GLAXOSMITHKLINE	0.0275MG/INH	N22051	001	Apr 27, 2007	Apr	NEWA
		<u>FOLIC ACID</u>						
		INJECTABLE; INJECTION						
		FOLIC ACID						
	+	ABRAXIS PHARM	5MG/ML	N89202	001	Feb 18, 1986	Jan	CTEC
		@ BEN VENUE	5MG/ML	N81066	001	Dec 29, 1993	Jan	DISC
		<u>FOLLITROPIN ALFA/BETA</u>						
		INJECTABLE; SUBCUTANEOUS						
		GONAL-F						
		@ EMD SERONO	37.5 IU/VIAL	N20378	003	May 25, 2000	Mar	CAHN
		@	37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar	CAHN
		@	75 IU/VIAL	N20378	001	Sep 29, 1997	Mar	CAHN
		@	150 IU/VIAL	N20378	002	Sep 29, 1997	Mar	CAHN
		@	150 IU/VIAL	N21765	003	Mar 25, 2004	Mar	CAHN
	+		450 IU/VIAL	N20378	005	Mar 26, 2004	Mar	CAHN
		@	1,050 IU/VIAL	N20378	004	Feb 28, 2001	Mar	CAHN
		GONAL-F RFF						
	+	EMD SERONO	75 IU/VIAL	N21765	002	Mar 25, 2004	Mar	CAHN
		<u>FORMOTEROL FUMARATE</u>						
		POWDER; INHALATION						
		FORADIL CERTIHALER						
	+	NOVARTIS	0.0085MG/INH	N21592	001	Dec 15, 2006	Jan	CRLD
		<u>FUROSEMIDE</u>						
		INJECTABLE; INJECTION						
		FUROSEMIDE						
AP		WOCKHARDT	10MG/ML	N77941	001	Mar 22, 2007	Mar	NEWA
		<u>GABAPENTIN</u>						
		TABLET; ORAL						
		GABAPENTIN						
AB	+	IVAX PHARMS	800MG	N76017	005	Apr 29, 2005	Feb	CRLD
		NEURONTIN						
AB		PFIZER PHARMS	800MG	N20882	002	Oct 09, 1998	Feb	CRLD
		<u>GEMFIBROZIL</u>						
		TABLET; ORAL						
		GEMFIBROZIL						
AB		PERRIGO R AND D	600MG	N78012	001	Mar 26, 2007	Mar	NEWA
		<u>GLIPIZIDE; METFORMIN HYDROCHLORIDE</u>						
		TABLET; ORAL						
		GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
>A>	AB	MYLAN	2.5MG;250MG	N78083	001	Apr 12, 2007	Apr	NEWA
>A>	AB		2.5MG;500MG	N78083	002	Apr 12, 2007	Apr	NEWA
>A>	AB		5MG;500MG	N78083	003	Apr 12, 2007	Apr	NEWA

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

>A>	AB	G AND W LABS	0.05%	N78162 001	Apr 24, 2007	Apr	NEWA
-----	----	--------------	-------	------------	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	@	ABRAXIS PHARM	1,000 UNITS/ML	N17979 001		Mar	DISC
	@		10,000 UNITS/ML	N17979 002		Mar	DISC
	@	WATSON LABS	1,000 UNITS/ML	N17064 002		Feb	CAHN
	@		2,500 UNITS/ML	N17064 015		Feb	CAHN
	@		3,000 UNITS/ML	N17064 016		Feb	CAHN
	@		4,000 UNITS/ML	N17064 017		Feb	CAHN
	@		5,000 UNITS/ML	N17064 003		Feb	CAHN
	@		6,000 UNITS/ML	N17064 018		Feb	CAHN
	@		7,500 UNITS/ML	N17064 019		Feb	CAHN
	@		10,000 UNITS/ML	N17064 004		Feb	CAHN
	@		20,000 UNITS/ML	N17064 005		Feb	CAHN
	@		40,000 UNITS/ML	N17064 006		Feb	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

VANTAS

>A>	+	INDEVUS	50MG	N21732 001	Oct 12, 2004	Apr	CAHN
>D>	+	VALERA	50MG	N21732 001	Oct 12, 2004	Apr	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	@	HERITAGE PHARMS INC	25MG	N86243 001		Feb	CAHN
	@		50MG	N86242 002		Feb	CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		ACTAVIS ELIZABETH	12.5MG	N40707 001	Feb 27, 2007	Feb	NEWA
AB		CARACO	25MG	N40810 001	Mar 27, 2007	Mar	NEWA
AB			50MG	N40810 002	Mar 27, 2007	Mar	NEWA
AB		EXCELLIUM	25MG	N40702 001	Mar 16, 2007	Mar	NEWA
AB			50MG	N40702 002	Mar 16, 2007	Mar	NEWA
AB		HERITAGE PHARMS INC	25MG	N85181 001		Feb	CAHN
AB			50MG	N85182 001		Feb	CAHN
AB		MYLAN	12.5MG	N40770 001	Jan 23, 2007	Feb	CTEC
			12.5MG	N40770 001	Jan 23, 2007	Jan	NEWA
AB			25MG	N40735 002	Jan 23, 2007	Jan	NEWA
AB			50MG	N40735 003	Jan 23, 2007	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		TEVA	12.5MG;7.5MG	N76980 001	Mar 07, 2007	Feb	NEWA
AB			12.5MG;15MG	N76980 003	Mar 07, 2007	Feb	NEWA
AB			25MG;15MG	N76980 002	Mar 07, 2007	Feb	NEWA

TABLET; ORAL

UNIRETIC

AB	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001	Jun 27, 1997	Feb	CFTG
AB		12.5MG;15MG	N20729 003	Feb 14, 2002	Feb	CFTG
AB	+	25MG;15MG	N20729 002	Jun 27, 1997	Feb	CFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

>D>	AB	+	INTERPHARM	5MG;200MG	N76642 002	Mar 18, 2004	Apr	CRLD
>A>	AB			5MG;200MG	N76642 002	Mar 18, 2004	Apr	CRLD

HYDROCORTISONE

TABLET; ORAL

CORTEF

AB	PHARMACIA AND UPJOHN	5MG	N08697 003		Mar	CFTG
AB		10MG	N08697 001		Mar	CFTG
		10MG	N08697 001		Feb	CMFD
AB	+	20MG	N08697 002		Mar	CTEC

HYDROCORTISONE

AB	STIEFEL	5MG	N40646 001	Mar 30, 2007	Mar	NEWA
AB		10MG	N40646 002	Mar 30, 2007	Mar	NEWA
AB		20MG	N40646 003	Mar 30, 2007	Mar	NEWA

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

>A>	AP	BARR	10MG/ML	N76444 001	Apr 25, 2003	Apr	CAHN
>D>	AP	MAYNE PHARMA USA	10MG/ML	N76444 001	Apr 25, 2003	Apr	CAHN
		@ WATSON LABS	10MG/ML	N74317 001	Aug 23, 1995	Feb	DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

	@	HOSPIRA	25MG/ML	N87416 001		Feb	DISC
	@		50MG/ML	N87546 001		Feb	DISC
	@	WATSON LABS	50MG/ML	N85779 001		Feb	DISC

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB	KVK-TECH INC	10MG	N40786 001	Mar 20, 2007	Mar	NEWA
AB		25MG	N40787 001	Mar 20, 2007	Mar	NEWA
AB		50MG	N40788 001	Mar 20, 2007	Mar	NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

+	SICOR PHARMS	1GM/20ML (50MG/ML)	N76657 001	Apr 04, 2007	Mar	NEWA
+		3GM/60ML (50MG/ML)	N76657 002	Apr 04, 2007	Mar	NEWA

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+	ACTELION	10UGM/ML (10UGM/ML)	N21779 002	Dec 08, 2005	Jan	CAHN
+		20UGM/2ML (10UGM/ML)	N21779 001	Dec 29, 2004	Jan	CAHN
+	ACTELION PHARM	10UGM/ML (10UGM/ML)	N21779 002	Dec 08, 2005	Feb	CAHN

SOLUTION; INHALATION

VENTAVIS

+	ACTELION PHARM	20UGM/2ML (10UGM/ML)	N21779	001	Dec 29, 2004	Feb	CAHN
---	----------------	----------------------	--------	-----	--------------	-----	------

IMIQUIMOD

CREAM; TOPICAL

ALDARA

+	GRACEWAY	5%	N20723	001	Feb 27, 1997	Jan	CAHN
---	----------	----	--------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

	@	HERITAGE PHARMS INC	25MG	N18851	001	May 18, 1984	Feb	CAHN
	@		50MG	N18851	002	May 18, 1984	Feb	CAHN
AB		MYLAN	25MG	N18858	001	Apr 20, 1984	Feb	CTEC
	@		50MG	N18858	002	Apr 20, 1984	Mar	DISC
AB	+		50MG	N70624	001	Sep 04, 1985	Mar	CRLD
AB		SANDOZ	25MG	N70673	001	Apr 29, 1987	Feb	CMFD
AB			50MG	N70674	001	Apr 29, 1987	Feb	CMFD

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	@	LUITPOLD	EQ 50MG BASE/2.5ML(EQ 20MG BASE/ML)	N21135	002	Mar 20, 2005	Feb	DISC
	@		EQ 75MG BASE/3.75ML(EQ 20MG BASE/ML)	N21135	003	Mar 29, 2005	Feb	DISC
			EQ 200MG BASE/10ML(EQ 20MG BASE/ML)	N21135	004	Feb 09, 2007	Feb	NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

AB		WEST WARD	30MG	N40591	001	Jan 10, 2007	Jan	NEWA
----	--	-----------	------	--------	-----	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB		HERITAGE PHARMS INC	25MG	N74014	001	Jan 29, 1993	Feb	CAHN
AB			50MG	N74014	002	Jan 29, 1993	Feb	CAHN
AB			75MG	N74014	003	Jan 29, 1993	Feb	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@	AMPHASTAR PHARM	15MG/ML	N76209	001	Jul 21, 2004	Mar	DISC
	@		30MG/ML	N76209	002	Jul 21, 2004	Mar	DISC
	@	APOTEX INC	30MG/ML	N75626	001	Jul 24, 2001	Mar	DISC
	@		30MG/ML	N77201	001	Oct 14, 2005	Mar	DISC
	@	GLAND PHARMA LTD	15MG/ML	N76722	001	Jul 27, 2004	Mar	DISC
	@		30MG/ML	N76722	002	Jul 27, 2004	Mar	DISC
AP		WOCKHARDT	15MG/ML	N77942	001	Mar 27, 2007	Mar	NEWA
AP			30MG/ML	N77942	002	Mar 27, 2007	Mar	NEWA
AP			30MG/ML	N77943	001	Mar 27, 2007	Mar	NEWA

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

>D>	+	GLAXOSMITHKLINE	EQ 250MG BASE	N22059 001	Mar 13, 2007	Apr	CAHN
	+		EQ 250MG BASE	N22059 001	Mar 13, 2007	Mar	NEWA
>A>	+	SMITHKLINE BEECHAM	EQ 250MG BASE	N22059 001	Mar 13, 2007	Apr	CAHN

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

@ PHARMACHEMIE

@

EQ 5MG BASE

EQ 25MG BASE

N73099 001 Mar 28, 1997 Jan DISC

N73101 001 Mar 28, 1997 Jan DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+	SANOFI AVENTIS US	7.5MG/VIAL	N21343 001	Jan 23, 2002	Jan	CAHN
	+		22.5MG/VIAL	N21379 001	Jul 24, 2002	Jan	CAHN
	+		30MG/VIAL	N21488 001	Feb 13, 2003	Jan	CAHN
	+		45MG/VIAL	N21731 001	Dec 14, 2004	Jan	CAHN

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR SF

AA		SIGMA TAU	1GM/10ML	N19257 002	Mar 28, 2007	Mar	NEWA
----	--	-----------	----------	------------	--------------	-----	------

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

	+	NOVEN	46.1MG/PATCH	N20575 002	May 21, 1996	Jan	CDFR
--	---	-------	--------------	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT		VINTAGE	2%	N40708 001	Feb 27, 2007	Feb	NEWA
----	--	---------	----	------------	--------------	-----	------

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		VINTAGE	4%	N40710 001	Feb 27, 2007	Feb	NEWA
----	--	---------	----	------------	--------------	-----	------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

LIDOCAINE AND TETRACAINE

>A>	+	GALDERMA LABS LP	7%;7%	N21717 001	Jun 29, 2006	Apr	CAHN
>D>	+	ZARS	7%;7%	N21717 001	Jun 29, 2006	Apr	CAHN

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

TRIOSTAT

>D>	AP	+	JONES PHARMA	EQ 0.01MG BASE/ML	N20105 001	Dec 31, 1991	Apr	CAHN
>A>	AP	+	KING PHARMS	EQ 0.01MG BASE/ML	N20105 001	Dec 31, 1991	Apr	CAHN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

	NEW RIVER	30MG	N21977 001	Feb 23, 2007	Feb	NEWA
		50MG	N21977 002	Feb 23, 2007	Feb	NEWA
+		70MG	N21977 003	Feb 23, 2007	Feb	NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

>A>	AB	WOCKHARDT	2.5MG	N78402 001	Apr 19, 2007	Apr	NEWA
>A>	AB		5MG	N78402 002	Apr 19, 2007	Apr	NEWA
>A>	AB		10MG	N78402 003	Apr 19, 2007	Apr	NEWA
>A>	AB		20MG	N78402 004	Apr 19, 2007	Apr	NEWA
>A>	AB		30MG	N78402 005	Apr 19, 2007	Apr	NEWA
>A>	AB		40MG	N78402 006	Apr 19, 2007	Apr	NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB		APOTEX INC	10MG	N77748 001	Feb 28, 2007	Feb	NEWA
AB			20MG	N77748 002	Feb 28, 2007	Feb	NEWA
AB			40MG	N77748 003	Feb 28, 2007	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

	@ ANDRX LABS LLC	10MG	N21316 001	Jun 26, 2002	Feb	DISC
--	------------------	------	------------	--------------	-----	------

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	ABBOTT	20MG;500MG	N21249 001	Dec 17, 2001	Mar	CAHN
+		20MG;750MG	N21249 002	Dec 17, 2001	Mar	CAHN
+		20MG;1GM	N21249 003	Dec 17, 2001	Mar	CAHN
+		40MG;1GM	N21249 004	Apr 27, 2006	Mar	CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	HOSPIRA	2GM/50ML (40MG/ML)	N20309 003	Jan 26, 2007	Jan	NEWA
+		4GM/50ML (80MG/ML)	N20309 002	Jun 24, 1994	Jan	CPOT
+		4GM/100ML (40MG/ML)	N20309 001	Jun 24, 1994	Jan	CPOT

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

LIALDA

+	SHIRE	1.2GM	N22000 001	Jan 16, 2007	Jan	NEWA
---	-------	-------	------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		TORRENT PHARMS	500MG	N77711 001	Jan 24, 2007	Jan	NEWA
AB			850MG	N77711 002	Jan 24, 2007	Jan	NEWA
AB			1GM	N77711 003	Jan 24, 2007	Jan	NEWA

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK	500MG;EQ 50MG BASE	N22044 001	Mar 30, 2007	Mar	NEWA
+		1GM;EQ 50MG BASE	N22044 002	Mar 30, 2007	Mar	NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

>D>		METHOTREXATE				
>D>	AP	+	ABRAXIS PHARM	EQ 50MG BASE/2ML (25MG/ML)	N40263 001	Feb 26, 1999 Apr CTNA
>D>	AP	+		EQ 250MG BASE/10ML (25MG/ML)	N40263 002	Feb 26, 1999 Apr CTNA
>D>	AP	+	MAYNE PHARMA USA	EQ 50MG BASE/2ML (25 MG/ML)	N11719 010	Dec 15, 2004 Apr CTNA
			METHOTREXATE LPF			
>A>		@	HOSPIRA	EQ 25MG BASE/ML	N11719 007	Mar 31, 1982 Apr CAHN
>D>		@	MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719 007	Mar 31, 1982 Apr CAHN
			METHOTREXATE PRESERVATIVE FREE			
>A>		@	HOSPIRA	EQ 20MG BASE/2ML (10 MG/ML)	N11719 014	Apr 13, 2005 Apr CAHN
>A>		@		EQ 500MG BASE/20ML (25 MG/ML)	N11719 013	Apr 13, 2005 Apr CAHN
>A>		@		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719 011	Apr 13, 2005 Apr CAHN
>D>		@	MAYNE PHARMA USA	EQ 20MG BASE/2ML (10 MG/ML)	N11719 014	Apr 13, 2005 Apr CAHN
>D>		@		EQ 500MG BASE/20ML (25 MG/ML)	N11719 013	Apr 13, 2005 Apr CAHN
>D>		+		EQ 1GM BASE/40ML (25MG/ML)	N11719 012	Apr 13, 2005 Apr CAHN
>D>		@		EQ 2.5GM BASE/100ML (25 MG/ML)	N11719 011	Apr 13, 2005 Apr CAHN
>A>			METHOTREXATE SODIUM			
>A>	AP	+	ABRAXIS PHARM	EQ 50MG BASE/2ML (25MG/ML)	N40263 001	Feb 26, 1999 Apr CTNA
>A>	AP	+		EQ 250MG BASE/10ML (25MG/ML)	N40263 002	Feb 26, 1999 Apr CTNA
>D>	AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340 001	Sep 16, 1986 Apr CTNA
>D>		+		EQ 250MG BASE/10ML (25 MG/ML)	N89343 001	Sep 16, 1986 Apr CTEC
>A>		@	HOSPIRA	EQ 2.5MG BASE/ML	N11719 004	Apr CAHN
>A>		@		EQ 20MG BASE/VIAL	N11719 001	Apr CAHN
>A>		@		EQ 25MG BASE/ML	N11719 005	Apr CAHN
>A>	AP	+		EQ 50MG BASE/2ML (25 MG/ML)	N11719 010	Dec 15, 2004 Apr CTNA
>A>		@		EQ 50MG BASE/VIAL	N11719 003	Apr CAHN
>A>		@		EQ 100MG BASE/VIAL	N11719 006	Apr CAHN
>D>		@	MAYNE PHARMA USA	EQ 2.5MG BASE/ML	N11719 004	Apr CAHN
>D>		@		EQ 20MG BASE/VIAL	N11719 001	Apr CAHN
>D>		@		EQ 25MG BASE/ML	N11719 005	Apr CAHN
>D>		@		EQ 50MG BASE/VIAL	N11719 003	Apr CAHN
>D>		@		EQ 100MG BASE/VIAL	N11719 006	Apr CAHN
>A>			METHOTREXATE SODIUM PRESERVATIVE FREE			
>A>	AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340 001	Sep 16, 1986 Apr CTNA
>A>	AP	+		EQ 250MG BASE/10ML (25MG/ML)	N89343 001	Sep 16, 1986 Apr CTEC
>A>	AP	+	GENERAMEDIX	EQ 50MG BASE/2ML (25MG/ML)	N40767 001	Apr 30, 2007 Apr NEWA
>A>	AP	+		EQ 250MG BASE/10ML (25MG/ML)	N40768 001	Apr 30, 2007 Apr NEWA
>A>	AP	+		EQ 1GM BASE/40ML (25MG/ML)	N40716 001	Apr 30, 2007 Apr NEWA
>A>	AP	+	HOSPIRA	EQ 1GM BASE/40ML (25MG/ML)	N11719 012	Apr 13, 2005 Apr CAHN
>A>		@		EQ 1GM BASE/VIAL	N11719 009	Apr 07, 1988 Apr CAHN
>D>		@	MAYNE PHARMA USA	EQ 1GM BASE/VIAL	N11719 009	Apr 07, 1988 Apr CAHN

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>A>		ALZA	18MG	N21121 001	Aug 01, 2000	Apr CAHN
>A>			27MG	N21121 004	Apr 01, 2002	Apr CAHN
>A>			36MG	N21121 002	Aug 01, 2000	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

>A>	+	ALZA	54MG	N21121 003	Dec 08, 2000	Apr	CAHN
>D>		JOHNSON AND JOHNSON	18MG	N21121 001	Aug 01, 2000	Apr	CAHN
			18MG	N21121 001	Aug 01, 2000	Feb	CAHN
>D>			27MG	N21121 004	Apr 01, 2002	Apr	CAHN
			27MG	N21121 004	Apr 01, 2002	Feb	CAHN
>D>			36MG	N21121 002	Aug 01, 2000	Apr	CAHN
			36MG	N21121 002	Aug 01, 2000	Feb	CAHN
>D>	+		54MG	N21121 003	Dec 08, 2000	Apr	CAHN
	+		54MG	N21121 003	Dec 08, 2000	Feb	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		BEDFORD LABS	EQ 40MG BASE/VIAL	N40662 001	Feb 21, 2007	Feb	NEWA
AP			EQ 125MG BASE/VIAL	N40641 002	Feb 21, 2007	Feb	NEWA
AP			EQ 500MG BASE/VIAL	N40641 003	Feb 21, 2007	Feb	NEWA
AP			EQ 500MG BASE/VIAL	N40709 001	Feb 21, 2007	Feb	NEWA
AP			EQ 1GM BASE/VIAL	N40641 004	Feb 21, 2007	Feb	NEWA
AP			EQ 1GM BASE/VIAL	N40709 002	Feb 21, 2007	Feb	NEWA

METRONIDAZOLE

GEL; VAGINAL

METROGEL-VAGINAL

AB	+	GRACEWAY	0.75%	N20208 001	Aug 17, 1992	Jan	CAHN
----	---	----------	-------	------------	--------------	-----	------

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>D>	AB	TEVA	250MG	N74377 003	May 16, 1995	Apr	CRLD
>A>	AB	+	250MG	N74377 003	May 16, 1995	Apr	CRLD
>D>		MEXITIL					
>D>	AB	BOEHRINGER INGELHEIM	150MG	N18873 002	Dec 30, 1985	Apr	DISC
>A>		@	150MG	N18873 002	Dec 30, 1985	Apr	DISC
>D>	AB		200MG	N18873 003	Dec 30, 1985	Apr	DISC
>A>		@	200MG	N18873 003	Dec 30, 1985	Apr	DISC
>D>	AB	+	250MG	N18873 004	Dec 30, 1985	Apr	DISC
>A>		@	250MG	N18873 004	Dec 30, 1985	Apr	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 1MG BASE/ML	N75293 001	Jun 20, 2000	Apr	CRLD	
>A>	AP	+	EQ 1MG BASE/ML	N75293 001	Jun 20, 2000	Apr	CRLD	
	AP	TAYLOR	EQ 1MG BASE/ML	N75494 001	Jun 30, 2000	Feb	CAHN	
	AP		EQ 5MG BASE/ML	N75494 002	Jun 30, 2000	Feb	CAHN	
		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
	AP	+	HOSPIRA	EQ 1MG BASE/ML	N75857 001	Jul 22, 2002	Feb	CTNA
	AP	+	EQ 5MG BASE/ML	N75857 002	Jul 22, 2002	Feb	CTNA	

MITOMYCIN

INJECTABLE; INJECTION

MITOZYTREX

	+	SUPERGEN	5MG/VIAL	N50763 001	Nov 14, 2002	Jan	CTNA
--	---	----------	----------	------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVANTRONE

AP	+	EMD SERONO	EQ 20MG BASE/10ML(2MG/ML)	N19297 001	Dec 23, 1987	Mar	CAHN
AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002	Dec 23, 1987	Mar	CAHN
AP	+		EQ 30MG BASE/15ML (2MG/ML)	N19297 003	Dec 23, 1987	Mar	CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

>A>	AB	TOLMAR	0.1%	N76591 001	Apr 18, 2007	Apr	NEWA
-----	----	--------	------	------------	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

BX		KING PHARMS	30MG	N21260 001	Mar 20, 2002	Mar	CAHN
BX			60MG	N21260 002	Mar 20, 2002	Mar	CAHN
			90MG	N21260 003	Mar 20, 2002	Mar	CAHN
			120MG	N21260 004	Mar 20, 2002	Mar	CAHN

KADIAN

>A>		ALPHARMA BRANDED	10MG	N20616 008	Apr 20, 2007	Apr	NEWA
>A>			20MG	N20616 001	Jul 03, 1996	Apr	CAHN
>A>	BX		30MG	N20616 004	Mar 09, 2001	Apr	CAHN
>A>			50MG	N20616 002	Jul 03, 1996	Apr	CAHN
>A>	BX		60MG	N20616 005	Mar 09, 2001	Apr	CAHN
>A>			80MG	N20616 006	Oct 27, 2006	Apr	CAHN
>A>	+		100MG	N20616 003	Jul 03, 1996	Apr	CAHN
>A>			200MG	N20616 007	Feb 27, 2007	Apr	CAHN
>D>		ALPHARMA US PHARMS	20MG	N20616 001	Jul 03, 1996	Apr	CAHN
>D>	BX		30MG	N20616 004	Mar 09, 2001	Apr	CAHN
>D>			50MG	N20616 002	Jul 03, 1996	Apr	CAHN
>D>	BX		60MG	N20616 005	Mar 09, 2001	Apr	CAHN
>D>			80MG	N20616 006	Oct 27, 2006	Apr	CAHN
>D>	+		100MG	N20616 003	Jul 03, 1996	Apr	CAHN
>D>			200MG	N20616 007	Feb 27, 2007	Apr	CAHN
>D>			200MG	N20616 007	Feb 27, 2007	Feb	NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

>A>	AP	BARR	10MG/ML	N74471 001	Mar 19, 1998	Apr	CAHN	
>A>	AP		20MG/ML	N74471 002	Mar 19, 1998	Apr	CAHN	
	AP	+	HOSPIRA	10MG/ML	N70914 001	Feb 03, 1989	Feb	CRLD
	AP	+		10MG/ML	N70915 001	Feb 03, 1989	Feb	CRLD
	AP	+		20MG/ML	N70916 001	Feb 03, 1989	Feb	CRLD
	AP	+		20MG/ML	N70918 001	Feb 03, 1989	Feb	CRLD
>D>	AP	MAYNE PHARMA USA	10MG/ML	N74471 001	Mar 19, 1998	Apr	CAHN	
>D>	AP		20MG/ML	N74471 002	Mar 19, 1998	Apr	CAHN	
		NUBAIN						
		@ ENDO PHARMS	10MG/ML	N18024 001		Feb	DISC	
		@	20MG/ML	N18024 002	May 27, 1982	Feb	DISC	

NAPROXEN

TABLET; ORAL

NAPROXEN

AB		GLENMARK PHARMS INC	250MG	N78250 001	Mar 28, 2007	Mar	NEWA
AB			375MG	N78250 002	Mar 28, 2007	Mar	NEWA
AB			500MG	N78250 003	Mar 28, 2007	Mar	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>A>	AB	GLENMARK PHARMS	EQ 250MG BASE	N78314 001	Apr 27, 2007	Apr	NEWA
>A>	AB		EQ 500MG BASE	N78314 002	Apr 27, 2007	Apr	NEWA
>A>	AB	INTERPHARM	EQ 250MG BASE	N78432 001	Apr 25, 2007	Apr	NEWA
>A>	AB		EQ 500MG BASE	N78432 002	Apr 25, 2007	Apr	NEWA

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

+		AGOURON	EQ 50MG BASE/SCOOPFUL	N20778 001	Mar 14, 1997	Mar	CDFR
---	--	---------	-----------------------	------------	--------------	-----	------

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

>D>	AB	+	TEVA	500MG	N60304 001		Apr	CTEC
>A>	AA	+		500MG	N60304 001		Apr	CTEC
>D>	AB		X GEN PHARMS	500MG	N65220 001	Jul 28, 2006	Apr	CTEC
>A>	AA			500MG	N65220 001	Jul 28, 2006	Apr	CTEC

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+		ALZA CORP	1.5MG/VIAL	N20920 001	Aug 10, 2001	Jan	CAHN
+		SCIOS	1.5MG/VIAL	N20920 001	Aug 10, 2001	Feb	CAHN

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

		@	ABBOTT	375MG	N20381 001	Jul 28, 1997	Mar	CAHN
>D>		+		500MG	N20381 002	Jul 28, 1997	Apr	CRLD
>A>				500MG	N20381 002	Jul 28, 1997	Apr	CRLD
		+		500MG	N20381 002	Jul 28, 1997	Mar	CAHN
		+		750MG	N20381 003	Jul 28, 1997	Mar	CAHN
		+		1GM	N20381 004	Jul 28, 1997	Mar	CAHN
			NIASPAN TITRATION STARTER PACK					
		@	ABBOTT	375MG;500MG;750MG	N20381 005	Jul 28, 1997	Mar	CAHN

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

>A>	AB		BARR	30MG	N77811 001	May 02, 2007	Apr	NEWA
>A>	AB		SUN PHARM INDS INC	30MG	N77067 001	Apr 17, 2007	Apr	NEWA
			NIMOTOP					
>D>		+	BAYER PHARMS	30MG	N18869 001	Dec 28, 1988	Apr	CFTG
>A>	AB	+		30MG	N18869 001	Dec 28, 1988	Apr	CFTG

NITROGLYCERINFILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN

AB1	GRACEWAY	0.1MG/HR	N89771	001	Aug 30, 1996	Jan	CAHN
AB1		0.2MG/HR	N89772	001	Aug 30, 1996	Jan	CAHN
AB1		0.4MG/HR	N89773	001	Aug 30, 1996	Jan	CAHN
AB1		0.6MG/HR	N89774	001	Aug 30, 1996	Jan	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	HOSPIRA	EQ 2MG BASE/ML	N77840	001	Jan 19, 2007	Jan	NEWA
AP	PLIVA	EQ 2MG BASE/ML	N77582	001	Dec 26, 2006	Mar	CAHN
AP	SPECTRUM PHARMS	EQ 2MG BASE/ML	N78180	001	Mar 26, 2007	Mar	NEWA
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER							
AP	HOSPIRA	EQ 0.64MG BASE/ML	N77348	001	Feb 01, 2007	Jan	NEWA
AP	MAYNE PHARMA USA	EQ 0.64MG BASE/ML	N76978	001	Feb 26, 2007	Feb	NEWA
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	PLIVA	EQ 2MG BASE/ML	N77387	001	Dec 26, 2006	Mar	CAHN
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER							
AP	+ GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N20403	001	Jan 31, 1995	Jan	CTNA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

AP	+ GRACEWAY	30MG/ML	N13055	001		Jan	CAHN
TABLET, EXTENDED RELEASE; ORAL							
NORFLEX							
	@ GRACEWAY	100MG	N12157	001		Jan	CAHN
ORPHENADRINE CITRATE							
AB	ACTAVIS TOTOWA	100MG	N40284	001	Jun 19, 1998	Mar	CAHN

OXANDROLONE

TABLET; ORAL

OXANDROLONE

AB	UPSHER SMITH	10MG	N78033	001	Mar 22, 2007	Mar	NEWA
----	--------------	------	--------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	KV PHARM	5MG	N77290	001	Dec 08, 2005	Mar	CTEC
AB	TYCO HLTHCARE	5MG	N78206	001	Mar 19, 2007	Mar	NEWA
AB	VINTAGE PHARMS	15MG	N77712	001	Jan 31, 2007	Jan	NEWA
AB		30MG	N77712	002	Jan 31, 2007	Jan	NEWA
ROXICODONE							
AB	+ XANODYNE PHARMS INC	15MG	N21011	001	Aug 31, 2000	Feb	CAHN
AB		30MG	N21011	002	Aug 31, 2000	Feb	CAHN

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA	EQ 10MG BASE	N77584	001	Mar 07, 2007	Feb	NEWA
AB		EQ 20MG BASE	N77584	002	Mar 07, 2007	Feb	NEWA
AB		EQ 30MG BASE	N77584	003	Mar 07, 2007	Feb	NEWA

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA	EQ 40MG BASE	N77584 004	Mar 07, 2007	Feb	NEWA
----	------------------	--------------	------------	--------------	-----	------

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

+	HOSPIRA INC	10MG/VIAL	N20122 001	Oct 11, 1991	Mar	CAHN
---	-------------	-----------	------------	--------------	-----	------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	HERITAGE PHARMS INC	400MG	N74877 001	Jul 08, 1997	Feb	CAHN
----	---------------------	-------	------------	--------------	-----	------

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

	@ IVAX PHARMS	EQ 0.05MG BASE	N76094 001	Sep 04, 2003	Mar	DISC
	@	EQ 0.25MG BASE	N76094 002	Sep 04, 2003	Mar	DISC
	@	EQ 1MG BASE	N76094 003	Sep 04, 2003	Mar	DISC
	@ PAR PHARM	EQ 0.05MG BASE	N76061 001	Nov 27, 2002	Mar	DISC
	@	EQ 0.25MG BASE	N76061 002	Nov 27, 2002	Mar	DISC
	@	EQ 1MG BASE	N76061 003	Nov 27, 2002	Mar	DISC
	PERMAX					
	@ VALEANT PHARM INTL	EQ 0.05MG BASE	N19385 001	Dec 30, 1988	Mar	DISC
AB		EQ 0.05MG BASE	N19385 001	Dec 30, 1988	Jan	CAHN
	@	EQ 0.25MG BASE	N19385 002	Dec 30, 1988	Mar	DISC
AB	+	EQ 0.25MG BASE	N19385 002	Dec 30, 1988	Jan	CAHN
	@	EQ 1MG BASE	N19385 003	Dec 30, 1988	Mar	DISC
AB		EQ 1MG BASE	N19385 003	Dec 30, 1988	Jan	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	+	SANDOZ	30MG	N87190 001		Feb	CRLD
AA		TG UNITED INC	30MG	N40083 001	Mar 07, 1997	Feb	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	ROXANE	7.5MG	N76963 002	Feb 27, 2007	Feb	NEWA
----	--------	-------	------------	--------------	-----	------

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIOCHIMICO	EQ 2GM BASE/VIAL	N65114 001	Nov 14, 2003	Feb	CAHN
+		EQ 3GM BASE/VIAL	N65114 002	Nov 14, 2003	Feb	CAHN
+		EQ 4GM BASE/VIAL	N65114 003	Nov 14, 2003	Feb	CAHN
+		EQ 40GM BASE/VIAL	N65157 001	Jul 12, 2004	Feb	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

	@ GRACEWAY	EQ 0.2MG BASE/INH	N19009 001	Dec 30, 1986	Jan	CAHN
+		EQ 0.2MG BASE/INH	N20014 001	Nov 30, 1992	Jan	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA		ANABOLIC LABS	17GM/SCOOPFUL	N77706 001	Sep 27, 2006	Jan	CAHN
----	--	---------------	---------------	------------	--------------	-----	------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

>D>	+	BRISTOL MYERS SQUIBB	80MG	N19898 008	Dec 18, 2001	Apr	CFTG
-----	---	----------------------	------	------------	--------------	-----	------

>A>	AB	+	80MG	N19898 008	Dec 18, 2001	Apr	CFTG
-----	----	---	------	------------	--------------	-----	------

PRAVASTATIN SODIUM

>A>	AB	RANBAXY	10MG	N76445 001	Apr 23, 2007	Apr	NEWA
-----	----	---------	------	------------	--------------	-----	------

>A>	AB		20MG	N76445 002	Apr 23, 2007	Apr	NEWA
-----	----	--	------	------------	--------------	-----	------

>A>	AB		40MG	N76445 003	Apr 23, 2007	Apr	NEWA
-----	----	--	------	------------	--------------	-----	------

>A>	AB		80MG	N76445 004	Apr 23, 2007	Apr	NEWA
-----	----	--	------	------------	--------------	-----	------

PREDNICARBATE

OINTMENT; TOPICAL

DERMATOP

AB	+	SANOFI AVENTIS US	0.1%	N19568 001	Sep 23, 1991	Feb	CFTG
----	---	-------------------	------	------------	--------------	-----	------

PREDNICARBATE

AB		ALTANA	0.1%	N77236 001	Mar 09, 2007	Feb	NEWA
----	--	--------	------	------------	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@	IVAX PHARMS	250MG	N84604 001	Jan	DISC
---	-------------	-------	------------	-----	------

@		375MG	N84595 001	Jan	DISC
---	--	-------	------------	-----	------

@		500MG	N84606 001	Jan	DISC
---	--	-------	------------	-----	------

@	WATSON LABS	250MG	N83287 001	Jan	DISC
---	-------------	-------	------------	-----	------

@		375MG	N84403 001	Jan	DISC
---	--	-------	------------	-----	------

@		500MG	N84280 001	Jan	DISC
---	--	-------	------------	-----	------

PRONESTYL

@	APOTHECON	250MG	N07335 001	Jan	DISC
---	-----------	-------	------------	-----	------

@		375MG	N07335 004	Jan	DISC
---	--	-------	------------	-----	------

@		500MG	N07335 003	Jan	DISC
---	--	-------	------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

PRONESTYL-SR

@	APOTHECON	500MG	N87361 001	Jan	DISC
---	-----------	-------	------------	-----	------

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

@	GLAXOSMITHKLINE	25MG	N11127 002	Feb	DISC
---	-----------------	------	------------	-----	------

PROCHLORPERAZINE

AB	+	G AND W LABS	25MG	N40058 001	Nov 24, 1993	Feb	CRLD
----	---	--------------	------	------------	--------------	-----	------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

COMPAZINE

@	GLAXOSMITHKLINE	EQ 5MG BASE/ML	N10742 002	Feb	DISC
---	-----------------	----------------	------------	-----	------

PROCHLORPERAZINE

@	BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759 001	Oct 01, 1982	Feb	DISC
---	-----------------	----------------	------------	--------------	-----	------

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989	Feb	CRLD
		@ HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	Feb	DISC
		@ WATSON LABS	EQ 5MG BASE/ML	N89530 001	Jul 08, 1987	Feb	DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

		@ GLAXOSMITHKLINE	EQ 15MG BASE	N21019 002	Oct 06, 1999	Jan	DISC
--	--	-------------------	--------------	------------	--------------	-----	------

TABLET; ORAL

COMPAZINE

		@ GLAXOSMITHKLINE	EQ 5MG BASE	N10571 001		Feb	DISC
--	--	-------------------	-------------	------------	--	-----	------

		@	EQ 10MG BASE	N10571 002		Feb	DISC
--	--	---	--------------	------------	--	-----	------

		@	EQ 25MG BASE	N10571 003		Feb	DISC
--	--	---	--------------	------------	--	-----	------

PROCHLORPERAZINE MALEATE

AB	+	SANDOZ	EQ 10MG BASE	N40101 002	Jul 19, 1996	Feb	CRLD
		@	EQ 25MG BASE	N40101 003	Jul 19, 1996	Feb	DISC

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TARO	6.25MG/5ML	N40718 001	Apr 04, 2007	Mar	NEWA
----	--	------	------------	------------	--------------	-----	------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

>A>	AB	KVK-TECH INC	12.5MG	N40712 002	May 04, 2007	Apr	NEWA
-----	----	--------------	--------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DOLENE

		@ HERITAGE PHARMS INC	65MG	N80530 001		Feb	CAHN
--	--	-----------------------	------	------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

AB		WYETH PHARMS INC	60MG	N18553 004	Mar 18, 1987	Jan	CTEC
----	--	------------------	------	------------	--------------	-----	------

AB			80MG	N18553 002	Apr 19, 1983	Jan	CTEC
----	--	--	------	------------	--------------	-----	------

AB			120MG	N18553 003	Apr 19, 1983	Jan	CTEC
----	--	--	-------	------------	--------------	-----	------

AB	+		160MG	N18553 001	Apr 19, 1983	Jan	CTEC
----	---	--	-------	------------	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

AB		MYLAN	60MG	N78022 001	Feb 15, 2007	Feb	NEWA
----	--	-------	------	------------	--------------	-----	------

AB			80MG	N78022 002	Feb 15, 2007	Feb	NEWA
----	--	--	------	------------	--------------	-----	------

AB			120MG	N78022 003	Feb 15, 2007	Feb	NEWA
----	--	--	-------	------------	--------------	-----	------

AB			160MG	N78022 004	Feb 15, 2007	Feb	NEWA
----	--	--	-------	------------	--------------	-----	------

AB		PAR PHARM	60MG	N78065 001	Jan 26, 2007	Jan	NEWA
----	--	-----------	------	------------	--------------	-----	------

AB			80MG	N78065 002	Jan 26, 2007	Jan	NEWA
----	--	--	------	------------	--------------	-----	------

AB			120MG	N78065 003	Jan 26, 2007	Jan	NEWA
----	--	--	-------	------------	--------------	-----	------

AB			160MG	N78065 004	Jan 26, 2007	Jan	NEWA
----	--	--	-------	------------	--------------	-----	------

TABLET; ORAL

INDERAL

		@ WYETH PHARMS INC	10MG	N16418 001		Jan	DISC
--	--	--------------------	------	------------	--	-----	------

		@	20MG	N16418 003		Jan	DISC
--	--	---	------	------------	--	-----	------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
 PYRIDOXINE HYDROCHLORIDE

	+	ABRAXIS PHARM	100MG/ML	N80618 001		Jan	CRLD
		@ WATSON LABS	100MG/ML	N80572 001		Jan	DISC

QUINIDINE SULFATE

TABLET; ORAL
 QUINIDINE SULFATE

		@ WATSON LABS	200MG	N83288 001		Mar	DISC
>D>	AB		300MG	N85583 001		Apr	DISC
>A>		@	300MG	N85583 001		Apr	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
 ACIPHEX

AB	+	EISAI MEDCL RES	20MG	N20973 002	Aug 19, 1999	Feb	CFTG
AB		RABEPRAZOLE SODIUM					
		TEVA	20MG	N76822 001	Feb 21, 2007	Feb	NEWA

RAMIPRIL

CAPSULE; ORAL
 ALTACE

		KING PHARMS	1.25MG	N19901 001	Jan 28, 1991	Jan	CTEC
			2.5MG	N19901 002	Jan 28, 1991	Jan	CTEC
			5MG	N19901 003	Jan 28, 1991	Jan	CTEC
	+		10MG	N19901 004	Jan 28, 1991	Jan	CTEC

RAMIPRIL

	@	COBALT	1.25MG	N76549 001	Oct 24, 2005	Jan	DISC
	@		2.5MG	N76549 002	Oct 24, 2005	Jan	DISC
	@		5MG	N76549 003	Oct 24, 2005	Jan	DISC
	@		10MG	N76549 004	Oct 24, 2005	Jan	DISC

TABLET; ORAL

ALTACE

>D>		COBALT	1.25MG	N22021 001	Feb 27, 2007	Apr	CAHN
			1.25MG	N22021 001	Feb 27, 2007	Feb	NEWA
>D>			2.5MG	N22021 002	Feb 27, 2007	Apr	CAHN
			2.5MG	N22021 002	Feb 27, 2007	Feb	NEWA
>D>			5MG	N22021 003	Feb 27, 2007	Apr	CAHN
			5MG	N22021 003	Feb 27, 2007	Feb	NEWA
>D>	+		10MG	N22021 004	Feb 27, 2007	Apr	CAHN
	+		10MG	N22021 004	Feb 27, 2007	Feb	NEWA
>A>		KING PHARMS	1.25MG	N22021 001	Feb 27, 2007	Apr	CAHN
>A>			2.5MG	N22021 002	Feb 27, 2007	Apr	CAHN
>A>			5MG	N22021 003	Feb 27, 2007	Apr	CAHN
>A>	+		10MG	N22021 004	Feb 27, 2007	Apr	CAHN

RANITIDINE HYDROCHLORIDE

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA		ALPHARMA US PHARMS	EQ 15MG BASE/ML	N76124 001	Feb 21, 2007	Feb	NEWA
		ZANTAC					
AA	+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N19675 001	Dec 30, 1988	Feb	CFTG

>A> RETAPAMULIN

>A> OINTMENT; TOPICAL

>A> ALTABAX

>A> + GLAXO GRP LTD 1% N22055 001 Apr 12, 2007 Apr NEWA

RIBAVIRIN

TABLET; ORAL

RIBAVIRIN

AB THREE RIVERS PHARMS 400MG N77456 002 Dec 05, 2005 Mar CTEC

AB + 600MG N77456 003 Dec 05, 2005 Mar CTEC

AB ZYDUS PHARMS USA 400MG N77094 002 Mar 16, 2007 Mar NEWA

AB 600MG N77094 003 Mar 16, 2007 Mar NEWA

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

>A> + PROCTER AND GAMBLE 75MG N20835 004 Apr 16, 2007 Apr NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

>A> JANSSEN PHARMA 12.5MG/VIAL N21346 004 Apr 12, 2007 Apr NEWA

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+ EMD SERONO EQ 0.05MG BASE/AMP N19863 001 Dec 28, 1990 Feb CAHN

@ EQ 0.5MG BASE/VIAL N20443 001 Sep 26, 1997 Feb CAHN

@ EQ 1MG BASE/VIAL N20443 002 Sep 26, 1997 Feb CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

AA RANBAXY EQ 20MG BASE/ML N78053 001 Feb 05, 2007 Feb CTEC

AB EQ 20MG BASE/ML N78053 001 Feb 05, 2007 Jan NEWA

AA ROXANE EQ 20MG BASE/ML N76934 001 Jun 30, 2006 Feb CTEC

ZOLOFT

AA + PFIZER EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Feb CTEC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 25MG BASE N77345 001 Feb 06, 2007 Jan NEWA

AB EQ 50MG BASE N77345 002 Feb 06, 2007 Jan NEWA

AB EQ 100MG BASE N77345 003 Feb 06, 2007 Jan NEWA

AB APOTEX INC EQ 25MG BASE N76882 001 Feb 06, 2007 Jan NEWA

AB EQ 50MG BASE N76882 002 Feb 06, 2007 Jan NEWA

AB EQ 100MG BASE N76882 003 Feb 06, 2007 Jan NEWA

AB AUROBINDO PHARMA EQ 25MG BASE N77206 001 Feb 06, 2007 Jan NEWA

AB EQ 50MG BASE N77206 002 Feb 06, 2007 Jan NEWA

AB EQ 100MG BASE N77206 003 Feb 06, 2007 Jan NEWA

AB COBALT EQ 25MG BASE N77663 001 Feb 06, 2007 Jan NEWA

AB EQ 50MG BASE N77663 002 Feb 06, 2007 Jan NEWA

AB EQ 100MG BASE N77663 003 Feb 06, 2007 Jan NEWA

>A> AB DR REDDYS LABS LTD EQ 25MG BASE N76442 001 Apr 30, 2007 Apr NEWA

>A> AB EQ 50MG BASE N76442 002 Apr 30, 2007 Apr NEWA

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>A>	AB	DR REDDYS LABS LTD	EQ 100MG BASE	N76442 003	Apr 30, 2007	Apr	NEWA
	AB	GENPHARM	EQ 25MG BASE	N76540 001	Mar 20, 2007	Mar	NEWA
	AB		EQ 50MG BASE	N76540 002	Mar 20, 2007	Mar	NEWA
	AB		EQ 100MG BASE	N76540 003	Mar 20, 2007	Mar	NEWA
	AB	INVAGEN PHARMS	EQ 25MG BASE	N77397 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77397 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77397 003	Feb 06, 2007	Jan	NEWA
	AB	LUPIN	EQ 25MG BASE	N77670 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77670 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77670 003	Feb 06, 2007	Jan	NEWA
	AB	MUTUAL PHARM	EQ 25MG BASE	N77818 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77818 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77818 003	Feb 06, 2007	Jan	NEWA
	AB	MYLAN	EQ 25MG BASE	N76671 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N76671 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N76671 003	Feb 06, 2007	Jan	NEWA
	AB	PLIVA HRVATSKA DOO	EQ 25MG BASE	N77299 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77299 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77299 003	Feb 06, 2007	Jan	NEWA
	AB	RANBAXY	EQ 25MG BASE	N77977 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77977 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77977 003	Feb 06, 2007	Jan	NEWA
			EQ 150MG BASE	N77977 004	Feb 06, 2007	Jan	NEWA
			EQ 200MG BASE	N77977 005	Feb 06, 2007	Jan	NEWA
	AB	ROXANE	EQ 25MG BASE	N76881 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N76881 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N76881 003	Feb 06, 2007	Jan	NEWA
	AB	SANDOZ	EQ 25MG BASE	N77713 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77713 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77713 003	Feb 06, 2007	Jan	NEWA
	AB	SUN PHARM INDS (IN)	EQ 25MG BASE	N78108 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N78108 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N78108 003	Feb 06, 2007	Jan	NEWA
	AB	TORRENT PHARMS	EQ 25MG BASE	N77765 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77765 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77765 003	Feb 06, 2007	Jan	NEWA
	AB	WATSON LABS	EQ 25MG BASE	N77162 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77162 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77162 003	Feb 06, 2007	Jan	NEWA
	AB	ZYDUS PHARMS USA	EQ 25MG BASE	N77106 001	Feb 06, 2007	Jan	NEWA
	AB		EQ 50MG BASE	N77106 002	Feb 06, 2007	Jan	NEWA
	AB		EQ 100MG BASE	N77106 003	Feb 06, 2007	Jan	NEWA

SEVOFLURANE

LIQUID; INHALATION

>A>		SOJOURN					
>A>	AN	MINRAD	100%	N77867 001	May 02, 2007	Apr	NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	AP	FRESENIUS MEDCL	900MG/100ML	N78177 001	Apr 12, 2007	Apr	NEWA
-----	----	-----------------	-------------	------------	--------------	-----	------

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER

+ HOSPIRA 5MEQ/ML N18947 001 Sep 05, 1984 Feb CRLD

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
SAIZEN

BX EMD SERONO 4MG/VIAL N19764 005 Jan 16, 2007 Feb CAHN

BX 5MG/VIAL N19764 002 Oct 08, 1996 Feb CAHN

@ 6MG/VIAL N19764 001 Oct 08, 1996 Feb CAHN

+ 8.8MG/VIAL N19764 003 Aug 29, 2000 Feb CAHN

BX SERONO 4MG/VIAL N19764 005 Jan 16, 2007 Jan NEWA

SEROSTIM

BX EMD SERONO 4MG/VIAL N20604 003 Jul 25, 1997 Feb CAHN

BX 5MG/VIAL N20604 002 Aug 23, 1996 Feb CAHN

BX 6MG/VIAL N20604 001 Aug 23, 1996 Feb CAHN

@ 8.8MG/VIAL N20604 004 Sep 06, 2001 Feb CAHN

>A> VALTROPIN

>A> BX LG LIFE 5MG/VIAL N21905 001 Apr 19, 2007 Apr NEWA

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

@ EMD SERONO 6MG/0.5ML N20604 005 Feb 11, 2005 Feb CAHN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2 MYLAN 80MG N77616 001 Feb 07, 2007 Jan NEWA

AB2 120MG N77616 002 Feb 07, 2007 Jan NEWA

AB2 160MG N77616 003 Feb 07, 2007 Jan NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

@ MUTUAL PHARM 80MG/ML; 16MG/ML N18374 001 Feb DISC

SUSPENSION; ORAL

BACTRIM PEDIATRIC

@ MUTUAL PHARM 200MG/5ML; 40MG/5ML N17560 002 Feb DISC

SEPTRA

@ MONARCH PHARMS 200MG/5ML; 40MG/5ML N17598 001 Feb DISC

SEPTRA GRAPE

@ MONARCH PHARMS 200MG/5ML; 40MG/5ML N17598 002 Feb 12, 1986 Feb DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ TEVA 200MG/5ML; 40MG/5ML N18812 002 Jun 10, 1983 Feb DISC

@ 200MG/5ML; 40MG/5ML N18812 001 Jan 28, 1983 Feb DISC

AB + TEVA PHARMS 200MG/5ML; 40MG/5ML N77612 001 Nov 13, 2006 Feb CRLD

AB VINTAGE 200MG/5ML; 40MG/5ML N77785 001 Jan 24, 2007 Jan NEWA

SULFATRIM

@ ACTAVIS MID ATLANTIC 200MG/5ML; 40MG/5ML N18615 002 Jan 07, 1983 Mar DISC

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB VINTAGE 400MG; 80MG N78060 002 Jan 25, 2007 Jan NEWA

AB 800MG; 160MG N78060 001 Jan 25, 2007 Jan NEWA

SULFANILAMIDECREAM; VAGINAL
AVC

>A>	+	AZUR PHARMA	15%	N06530 003	Jan 27, 1987	Apr	CAHN
>D>	+	PHARMELLE	15%	N06530 003	Jan 27, 1987	Apr	CAHN

SUPPOSITORY; VAGINAL
AVC

>A>	@	AZUR PHARMA	1.05GM	N06530 004	Jan 27, 1987	Apr	CAHN
>D>	@	PHARMELLE	1.05GM	N06530 004	Jan 27, 1987	Apr	CAHN

SULFASALAZINETABLET; ORAL
SULFASALAZINE

@	HERITAGE PHARMS INC	500MG	N80197 001			Feb	CAHN
---	---------------------	-------	------------	--	--	-----	------

SULINDACTABLET; ORAL
SULINDAC

@	HERITAGE PHARMS INC	150MG	N73262 002	Sep 06, 1991	Feb	CAHN
@		200MG	N73262 001	Sep 06, 1991	Feb	CAHN

TADALAFILTABLET; ORAL
CIALIS

>A>		LILLY	5MG	N21368 001	Nov 21, 2003	Apr	CAHN
>A>			10MG	N21368 002	Nov 21, 2003	Apr	CAHN
>A>	+		20MG	N21368 003	Nov 21, 2003	Apr	CAHN
>D>		LILLY ICOS	5MG	N21368 001	Nov 21, 2003	Apr	CAHN
>D>			10MG	N21368 002	Nov 21, 2003	Apr	CAHN
>D>	+		20MG	N21368 003	Nov 21, 2003	Apr	CAHN

TAMOXIFEN CITRATETABLET; ORAL
NOLVADEX

@	ASTRAZENECA	EQ 10MG BASE	N17970 001			Mar	DISC
@		EQ 20MG BASE	N17970 002	Mar 21, 1994	Mar	DISC	

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION
DRAXIMAGE MDP-10

AP	+	DRAXIMAGE	N/A	N18035 001		Jan	CTNA
		DRAXIMAGE MDP-25					
	+	DRAXIMAGE	N/A	N18035 002	Feb 27, 2004	Jan	NEWA

TEGASEROD MALEATETABLET; ORAL
ZELNORM

@	NOVARTIS	EQ 2MG BASE	N21200 001	Jul 24, 2002	Mar	DISC
@		EQ 6MG BASE	N21200 002	Jul 24, 2002	Mar	DISC

TERBUTALINE SULFATETABLET; ORAL
BRETHINE

>D>	AB	AAIPHARMA LLC	2.5MG	N17849 001		Apr	DISC
-----	----	---------------	-------	------------	--	-----	------

	TABLET; ORAL					
>D>	BRETHINE					
>A>	@ AAIPHARMA LLC	2.5MG	N17849 001		Apr	DISC
>D>	AB +	5MG	N17849 002		Apr	DISC
>A>	@	5MG	N17849 002		Apr	DISC
	<u>TERCONAZOLE</u>					
	SUPPOSITORY; VAGINAL					
	TERCONAZOLE					
AB	TARO	80MG	N77553 001	Mar 09, 2007	Feb	NEWA
	<u>TETRACYCLINE HYDROCHLORIDE</u>					
	CAPSULE; ORAL					
	ACHROMYCIN V					
>A>	@ HERITAGE PHARMS INC	250MG	N50278 003		Apr	CAHN
>A>	@	500MG	N50278 001		Apr	CAHN
>D>	@ RADIUS PHARMS	250MG	N50278 003		Apr	CAHN
>D>	@	500MG	N50278 001		Apr	CAHN
	<u>THALIDOMIDE</u>					
	CAPSULE; ORAL					
	THALOMID					
	CELGENE	150MG	N20785 004	Jan 10, 2007	Jan	NEWA
	<u>THEOPHYLLINE</u>					
	TABLET; ORAL					
	QUIBRON-T					
	@ MONARCH PHARMS	300MG	N88656 001	Aug 22, 1985	Feb	DISC
	THEOLAIR					
	+ GRACEWAY	125MG	N86399 001		Mar	CAHN
	+	250MG	N86399 002		Mar	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	QUIBRON-T/SR					
	@ MONARCH PHARMS	300MG	N87563 001	Jun 21, 1983	Feb	DISC
	<u>TOLCAPONE</u>					
	TABLET; ORAL					
	TASMAR					
	VALEANT PHARM INTL	100MG	N20697 001	Jan 29, 1998	Jan	CAHN
	+	200MG	N20697 002	Jan 29, 1998	Jan	CAHN
	<u>TRAMADOL HYDROCHLORIDE</u>					
	TABLET, EXTENDED RELEASE; ORAL					
	ULTRAM ER					
>D>	BIOVAIL LABS INTL	100MG	N21692 001	Sep 08, 2005	Apr	CRLD
>A>	+	100MG	N21692 001	Sep 08, 2005	Apr	CRLD
		100MG	N21692 001	Sep 08, 2005	Feb	CTNA
		200MG	N21692 002	Sep 08, 2005	Feb	CTNA
>D>	+	300MG	N21692 003	Sep 08, 2005	Apr	CRLD
>A>		300MG	N21692 003	Sep 08, 2005	Apr	CRLD
	+	300MG	N21692 003	Sep 08, 2005	Feb	CTNA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	APOTEX	50MG	N71258 001	Mar 25, 1987	Mar	CAHN
----	--------	------	------------	--------------	-----	------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

@ APOTHECON 0.5%

N83943 001 Mar DISC

TRIAMCINOLONE ACETONIDE

>D>	AT	ALTANA	0.5%	N85692 002	Apr	CRLD
-----	----	--------	------	------------	-----	------

>A>	AT	+	0.5%	N85692 002	Apr	CRLD
-----	----	---	------	------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	RANBAXY	EQ 500MG BASE	N76588 001	Jan 31, 2007	Jan	NEWA
----	---------	---------------	------------	--------------	-----	------

AB		EQ 1GM BASE	N76588 002	Jan 31, 2007	Jan	NEWA
----	--	-------------	------------	--------------	-----	------

VALTREX

AB	GLAXOSMITHKLINE	EQ 500MG BASE	N20487 001	Jun 23, 1995	Jan	CFTG
----	-----------------	---------------	------------	--------------	-----	------

AB	+	EQ 1GM BASE	N20487 002	Jun 23, 1995	Jan	CFTG
----	---	-------------	------------	--------------	-----	------

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

>A>	+	INDEVUS PHARMS	40MG/ML	N20892 001	Sep 25, 1998	Apr	CAHN
-----	---	----------------	---------	------------	--------------	-----	------

>D>	+	VALERA	40MG/ML	N20892 001	Sep 25, 1998	Apr	CAHN
-----	---	--------	---------	------------	--------------	-----	------

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPTIN

@ FSC 2.5MG/ML

N18485 001 Feb DISC

VERAPAMIL HYDROCHLORIDE

@ LUITPOLD 2.5MG/ML

N70225 001 Nov 12, 1985 Feb DISC

AP	+		2.5MG/ML	N70617 001	Nov 12, 1985	Feb	CRLD
----	---	--	----------	------------	--------------	-----	------

TABLET; ORAL

CALAN

AB	+	GD SEARLE LLC	120MG	N18817 002	Sep 10, 1984	Feb	CRLD
----	---	---------------	-------	------------	--------------	-----	------

ISOPTIN

@ FSC 40MG

N18593 003 Nov 23, 1987 Feb DISC

@ 80MG

N18593 001 Mar 08, 1982 Feb DISC

@ 120MG

N18593 002 Mar 08, 1982 Feb DISC

VERAPAMIL HYDROCHLORIDE

@ HERITAGE PHARMS INC 80MG

N71880 001 Apr 05, 1988 Feb CAHN

@ 120MG

N71881 001 Apr 05, 1988 Feb CAHN

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLAST

>A>							
-----	--	--	--	--	--	--	--

>A>	+	NOVARTIS	EQ 5MG BASE/100ML	N21817 001	Apr 16, 2007	Apr	NEWA
-----	---	----------	-------------------	------------	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

>D>		SANOFI AVENTIS US	5MG	N19908 001	Dec 16, 1992	Apr	CFTG
>A>	AB		5MG	N19908 001	Dec 16, 1992	Apr	CFTG
>D>		+	10MG	N19908 002	Dec 16, 1992	Apr	CFTG
>A>	AB	+	10MG	N19908 002	Dec 16, 1992	Apr	CFTG

>A>		ZOLPIDEM TARTRATE					
>A>	AB	APOTEX INC	5MG	N77884 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77884 002	Apr 23, 2007	Apr	NEWA
>A>	AB	AUROBINDO PHARMA	5MG	N78413 001	May 04, 2007	Apr	NEWA
>A>	AB		10MG	N78413 002	May 04, 2007	Apr	NEWA
>A>	AB	CARACO	5MG	N77359 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77359 002	Apr 23, 2007	Apr	NEWA
>A>	AB	CARLSBAD	5MG	N77990 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77990 002	Apr 23, 2007	Apr	NEWA
>A>	AB	DR REDDYS LABS LTD	5MG	N77985 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77985 002	Apr 23, 2007	Apr	NEWA
>A>	AB	GENPHARM	5MG	N78016 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N78016 002	Apr 23, 2007	Apr	NEWA
>A>	AB	LEK PHARMS DD	5MG	N77322 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77322 002	Apr 23, 2007	Apr	NEWA
>A>	AB	MUTUAL PHARMA	5MG	N77288 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77288 002	Apr 23, 2007	Apr	NEWA
>A>	AB	MYLAN	5MG	N76578 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N76578 002	Apr 23, 2007	Apr	NEWA
>A>	AB	PAR PHARM	5MG	N76062 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N76062 002	Apr 23, 2007	Apr	NEWA
>A>	AB	RANBAXY	5MG	N78055 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N78055 002	Apr 23, 2007	Apr	NEWA
>A>	AB	ROXANE	5MG	N77214 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77214 002	Apr 23, 2007	Apr	NEWA
>A>	AB	SYNTHON PHARMS	5MG	N77540 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77540 002	Apr 23, 2007	Apr	NEWA
>A>	AB	TEVA	5MG	N76410 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N76410 002	Apr 23, 2007	Apr	NEWA
>A>	AB	WATSON LABS	5MG	N77773 001	Apr 23, 2007	Apr	NEWA
>A>	AB		10MG	N77773 002	Apr 23, 2007	Apr	NEWA

>A>		TABLET, ORALLY DISINTEGRATING; ORAL					
-----	--	-------------------------------------	--	--	--	--	--

>A>		TOVALT ODT					
>A>		BIOVAIL LABS INTL	5MG	N21412 001	Apr 25, 2007	Apr	NEWA
>A>		+	10MG	N21412 002	Apr 25, 2007	Apr	NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB		COREPHARMA	25MG	N77876 001	Feb 21, 2007	Feb	NEWA
AB			50MG	N77876 002	Feb 21, 2007	Feb	NEWA
AB			100MG	N77876 003	Feb 21, 2007	Feb	NEWA

OTC DRUG PRODUCT LIST - 27TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2007

2-1

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+ ENTURIA INC	2%;70% (26ML)	N20832 006	Nov 21, 2006	Jan	CAHN
+	2%;70% (3ML)	N20832 001	Jul 14, 2000	Jan	CAHN
+	2%;70% (10.5ML)	N20832 004	Aug 20, 2003	Jan	CAHN

CHLORAPREP ONE-STEP FREPP

+ ENTURIA INC	2%;70% (1.5ML)	N20832 003	Apr 26, 2002	Jan	CAHN
---------------	----------------	------------	--------------	-----	------

CHLORAPREP WITH TINT

+ ENTURIA INC	2%;70% (3ML)	N20832 007	Oct 10, 2006	Feb	NEWA
+	2%;70% (26ML)	N20832 002	May 03, 2005	Jan	CAHN
+	2%;70% (10.5ML)	N20832 005	Apr 03, 2006	Jan	CAHN

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ ENTURIA INC	2%;70% (0.67ML)	N21555 001	Oct 07, 2002	Jan	CAHN
---------------	-----------------	------------	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+ ENTURIA INC	2%;70% (1.75ML)	N21555 002	May 10, 2005	Jan	CAHN
---------------	-----------------	------------	--------------	-----	------

>A> DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

>A> CAPSULE; ORAL

>A> ADVIL PM

>A> + WYETH CONS	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N21393 001	Dec 21, 2005	Apr	CAIN
------------------	--	------------	--------------	-----	------

>D> DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN POTASSIUM

>D> CAPSULE; ORAL

>D> ADVIL PM

>D> + WYETH CONS	25MG;200MG	N21393 001	Dec 21, 2005	Apr	CAIN
------------------	------------	------------	--------------	-----	------

DOXYLAMINE SUCCINATE

TABLET; ORAL

UNISOM

+ CHATTEM	25MG	N18066 001		Feb	CAHN
+ MCNEIL CONS	25MG	N18066 001		Jan	CAHN

FAMOTIDINE

TABLET, CHEWABLE; ORAL

FAMOTIDINE

+ PERRIGO	10MG	N75715 001	Aug 22, 2003	Mar	CRLD
-----------	------	------------	--------------	-----	------

PEPCID AC

@ MERCK	10MG	N20801 001	Sep 24, 1998	Mar	DISC
---------	------	------------	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

>D> HUMABID

>D> + ADAMS RESP THERAP	1.2GM	N21282 002	Dec 18, 2002	Apr	CTNA
-------------------------	-------	------------	--------------	-----	------

>A> HUMIBID

>A> + ADAMS RESP THERAP	1.2GM	N21282 002	Dec 18, 2002	Apr	CTNA
-------------------------	-------	------------	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

+ WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N20402 001	Apr 20, 1995	Jan	CAIN
--------------	---------------------------------------	------------	--------------	-----	------

CAPSULE; ORAL

ADVIL MIGRAINE LIQUI-GELS

+	WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT	N20402 002	Mar 16, 2000	Jan	CAIN
---	------------	---------------------------------------	------------	--------------	-----	------

>D> IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

>D> CAPSULE; ORAL

>D> ADVIL COLD AND SINUS

>D>	+	WYETH CONS	200MG;30MG	N21374 001	May 30, 2002	Apr	CAIN
-----	---	------------	------------	------------	--------------	-----	------

>A> IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> ADVIL COLD AND SINUS

>A>	+	WYETH CONS	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N21374 001	May 30, 2002	Apr	CAIN
-----	---	------------	--	------------	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+	BAUSCH AND LOMB	EQ 0.025% BASE	N21996 001	Dec 01, 2006	Jan	CAHN
---	-----------------	----------------	------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+	MCNEIL	2MG	N20448 001	Jul 24, 1997	Jan	CTNA
---	--------	-----	------------	--------------	-----	------

LORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE REDIDOSE

>A>	+	RANBAXY	10MG	N77153 001	Apr 11, 2007	Apr	NEWA
-----	---	---------	------	------------	--------------	-----	------

NONOXYNOL-9

SPONGE; VAGINAL

TODAY

+	ALLENDAL PHARMS	1GM	N18683 001	Apr 01, 1983	Feb	CMFD
---	-----------------	-----	------------	--------------	-----	------

ORLISTAT

CAPSULE; ORAL

ALLI

+	GLAXOSMITHKLINE CONS	60MG	N21887 001	Feb 07, 2007	Feb	NEWA
---	----------------------	------	------------	--------------	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 12 HOUR

+	MCNEIL CONS	120MG	N73585 001	Oct 31, 1991	Mar	CAHN
---	-------------	-------	------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL

ZANTAC 75

@	BOEHRINGER INGELHEIM	EQ 75MG BASE	N20745 001	Feb 26, 1998	Feb	CAHN
---	----------------------	--------------	------------	--------------	-----	------

TABLET; ORAL

ZANTAC 150

+	BOEHRINGER INGELHEIM	EQ 150MG BASE	N21698 001	Aug 31, 2004	Jan	CAHN
---	----------------------	---------------	------------	--------------	-----	------

ZANTAC 75

BOEHRINGER INGELHEIM	EQ 75MG BASE	N20520 001	Dec 19, 1995	Jan	CAHN
----------------------	--------------	------------	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2007

NO APRIL 2007 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2007 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACARBOSE - PRECOSE</u>					
020482 001	>A> 4904769	Sep 06, 2009			
<u>ACARBOSE - PRECOSE</u>					
020482 002	>A> 4904769	Sep 06, 2009			
<u>ACARBOSE - PRECOSE</u>					
020482 004	>A> 4904769	Sep 06, 2009			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>					
020983 001	6558651	Dec 19, 2016	DP		
	6743413	Jun 01, 2021	DP	U-716	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>					
021287 001	>A> 4661491	Jan 18, 2011		U-706	
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>					
021985 001	>A> 5559111	Apr 04, 2015	DS DP	U-3	NCE Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>					
021985 002	>A> 5559111	Apr 04, 2015	DS DP	U-3	NCE Mar 05, 2012
<u>ANIDULAFUNGIN - ERAXIS</u>					
021632 001	>A> 7198796	Jun 13, 2022	DP		
<u>ANIDULAFUNGIN - ERAXIS</u>					
021632 002	5965525	Oct 12, 2016	DS DP	U-540	
	6384013	Mar 19, 2012	DS		
	6743777	Mar 19, 2012		DP U-540	
	6960564	Apr 12, 2021		DP U-540	
	>A> 7198796	Jun 13, 2022	DP		
<u>ARFORMOTEROL TARTRATE - BROVANA</u>					
021912 001	5795564	Apr 03, 2012		U-793	
	6068833	Apr 03, 2012		U-793	
	6589508	Apr 03, 2012		U-793	
	6866839	Apr 03, 2012		U-793	
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>					
021881 001	7169381	Sep 01, 2024	DS DP		
<u>ATORVASTATIN CALCIUM - LIPITOR</u>					
020702 001				I-523	Mar 02, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>					
020702 002				I-523	Mar 02, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>					
020702 003				I-523	Mar 02, 2010
<u>ATORVASTATIN CALCIUM - LIPITOR</u>					
020702 004				I-523	Mar 02, 2010
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - CAPITAL SOLEIL 15</u>					
021501 001				NC NP	Jul 21, 2009 Oct 02, 2009
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 20</u>					
021471 001				NC	Oct 05, 2009
<u>BALSALAZIDE DISODIUM - COLAZAL</u>					
020610 001				ODE PED	Dec 20, 2013 Jun 20, 2014
<u>BORTEZOMIB - VELCADE</u>					
021602 001	5780454	May 03, 2017	DP		
<u>BOSENTAN - TRACLEER</u>					
021290 001				M-64	Feb 15, 2010
<u>BOSENTAN - TRACLEER</u>					
021290 002				M-64	Feb 15, 2010
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 001	>A> 6899099	Dec 23, 2018		U-529	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 002	6899099	Dec 23, 2018		U-529	
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>					
021929 001	>A> 6641800	Sep 23, 2012	DP		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>					
021929 002	>A> 6641800	Sep 23, 2012	DP		
<u>BUPROPION HYDROCHLORIDE - BUPROPION HYDROCHLORIDE</u>					
077284 002				PC	Jun 12, 2007
<u>BUPROPION HYDROCHLORIDE - BUPROPION HYDROCHLORIDE</u>					
077415 002				PC	Jun 12, 2007
<u>CARVEDILOL - COREG</u>					
020297 001				M-61 PED	Feb 23, 2010 Aug 23, 2010
<u>CARVEDILOL - COREG</u>					
020297 002				M-61 PED	Feb 23, 2010 Aug 23, 2010
<u>CARVEDILOL - COREG</u>					
020297 003				M-61 PED	Feb 23, 2010 Aug 23, 2010
<u>CARVEDILOL - COREG</u>					
020297 004				M-61 PED	Feb 23, 2010 Aug 23, 2010
<u>CELECOXIB - CELEBREX</u>					
020998 004	5466823	Nov 30, 2013	DS	I-466	Jul 29, 2008
	5466823*PED	May 30, 2014		NPP	Dec 15, 2009
	5563165	Nov 30, 2013	DP	PED	Jun 15, 2010
	5563165*PED	May 30, 2014		PED	Jan 29, 2009
	5760068	Jun 02, 2015		U-672	
	5760068*PED	Dec 02, 2015			
<u>CETRORELIX - CETROTIDE</u>					
021197 001	>A> 5198533	Oct 24, 2010	DS DP		
<u>CETRORELIX - CETROTIDE</u>					
021197 002	>A> 5198533	Oct 24, 2010	DS DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>					
020832 006	6991394	Jan 31, 2024	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>					
020832 002	6991394	Jan 31, 2024	DP		
<u>CICLESONIDE - OMNARIS</u>					
022004 001	5482934	Jan 09, 2013	DS DP	U-557	
	6767901	Oct 21, 2020	DP		
	6939559	Apr 21, 2019	DP		
<u>CLOBETASOL PROPIONATE - OLUX E</u>					
022013 001	6730288	Sep 08, 2019	DP	NP	Jan 12, 2010
	7029659	Sep 08, 2019	DP		
<u>CLOZAPINE - FAZACLO ODT</u>					
021590 001	5178878	Jan 12, 2010	DP		
<u>CLOZAPINE - FAZACLO ODT</u>					
021590 002	5178878	Jan 12, 2010	DP		
<u>CLOZAPINE - FAZACLO ODT</u>					
021590 003	5178878	Jan 12, 2010	DP		
<u>COLESTIPOL HYDROCHLORIDE - COLESTIPOL HYDROCHLORIDE</u>					
077510 001				PC	Jun 12, 2007
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>					
021697 001				I-526	Feb 28, 2010
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>					
021777 001				NDF	Feb 01, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>					
021777 002				NDF	Feb 01, 2010
<u>CYTARABINE - DEPOCYT</u>					
021041 001	>A> 5455044	May 14, 2013	U-806		
	>A> 5723147	Mar 03, 2015	DP U-806		
	>A> 5962016	Jan 31, 2017	DP U-806		
	>A> 6071534	Feb 18, 2008	DP		
	>A> 7198801	Jun 25, 2022	DP		
<u>DASATINIB - SPRYCEL</u>					
021986 001	7153856	Apr 28, 2020		U-780	
<u>DASATINIB - SPRYCEL</u>					
021986 002	7153856	Apr 28, 2020		U-780	
<u>DASATINIB - SPRYCEL</u>					
021986 003	7153856	Apr 28, 2020		U-780	
<u>DECITABINE - DACOGEN</u>					
021790 001				ODE	May 02, 2013
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>					
021802 004	5837284	Dec 04, 2015	DP		
	5908850	Dec 04, 2015		U-678	
	6228398	Nov 01, 2019	DP	U-676	
	6528530	Dec 04, 2015	DP		
	6635284	Dec 04, 2015	DP	U-677	
	6730325	Nov 01, 2019	DP	U-676	
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>					
021234 001	4948805	Nov 09, 2007	DS	NE	Jan 31, 2010
	5607690	Apr 13, 2014	DP	NDF	Jan 31, 2010
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>					
020690 001				>A> I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>					
020690 002				>A> I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>					
021719 001				>A> I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 001				>A> I-529	Oct 13, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>					
021720 002				>A> I-529	Oct 13, 2009
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>					
021676 001	7163931	Dec 20, 2021		U-1 I-522	Jan 26, 2010
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>					
021427 001	>A> 5023269	Jun 11, 2013	DS DP	U-795 I-524	Feb 23, 2010
	>A> 5023269	Jun 11, 2013	DS DP	U-799	
	>A> 5023269	Jun 11, 2013	DS DP	U-797	
	>A> 5023269	Jun 11, 2013	DS DP	U-796	
	>A> 5023269	Jun 11, 2013	DS DP	U-605	
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>					
021427 002	>A> 5023269	Jun 11, 2013	DS DP	U-797 I-524	Feb 23, 2010
	>A> 5023269	Jun 11, 2013	DS DP	U-799	
	>A> 5023269	Jun 11, 2013	DS DP	U-796	
	>A> 5023269	Jun 11, 2013	DS DP	U-795	
	>A> 5023269	Jun 11, 2013	DS DP	U-605	
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>					
021427 004	>A> 5023269	Jun 11, 2013	DS DP	U-795 I-524	Feb 23, 2010
	>A> 5023269	Jun 11, 2013	DS DP	U-797	
	>A> 5023269	Jun 11, 2013	DS DP	U-799	
	>A> 5023269	Jun 11, 2013	DS DP	U-796	
	>A> 5023269	Jun 11, 2013	DS DP	U-605	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DUTASTERIDE - AVODART</u>					
021319 001	>A> 5565467	Nov 20, 2015	DS DP		
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>					
021937 001	>A> 6639071	Feb 14, 2018	DS	>A> NCE >A> PED	Jul 02, 2008 Jan 02, 2009
<u>EMTRICITABINE - EMTRIVA</u>					
021500 001	5210085	May 11, 2010		U-257	
	5814639	Sep 29, 2015	DS DP		
	5914331	Sep 29, 2015	DS		
<u>ENTECAVIR - BARACLUDE</u>					
021798 001	5908638	Jul 26, 2015		DP	
<u>EPLERENONE - INSPRA</u>					
021437 001	4559332	Aug 11, 2007	DS DP	U-537	
	7157101	Dec 08, 2019		DP U-664	
<u>EPLERENONE - INSPRA</u>					
021437 002	4559332	Aug 11, 2007	DS DP	U-537	
	7157101	Dec 08, 2019		DP U-664	
<u>EPLERENONE - INSPRA</u>					
021437 003	4559332	Aug 11, 2007	DS DP	U-537	
	7157101	Dec 08, 2019		DP U-664	
<u>ERTAPENEM SODIUM - INVANZ</u>					
021337 001	5478820	Nov 21, 2015	DS DP	U-160	
	5478820*PED	May 21, 2016			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 001	>A> 4738974	Sep 01, 2007	DS DP	U-635	
	>A> 4738974	Sep 01, 2007	DS DP	U-770	
	>A> 4738974	Sep 01, 2007	DS DP	U-373	
	>A> 4738974*PED	Mar 01, 2008		U-373	
	>A> 4853230	Sep 01, 2007		DP U-729	
	>A> 4853230	Sep 01, 2007		DP U-770	
	>A> 4853230	Sep 01, 2007		DP U-373	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021153 002	>A> 4738974	Sep 01, 2007	DS DP	U-770	
	>A> 4738974	Sep 01, 2007	DS DP	U-635	
	>A> 4738974	Sep 01, 2007	DS DP	U-373	
	>A> 4738974*PED	Mar 01, 2008		U-373	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021957 001	>A> 4738974	Sep 01, 2007	DS DP	U-773	
	>A> 4738974	Sep 01, 2007	DS DP	U-729	
	>A> 4783974*PED	Mar 01, 2008			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>					
021957 002	>A> 4738974	Sep 01, 2007	DS DP	U-773	
	>A> 4738974	Sep 01, 2007	DS DP	U-729	
	>A> 4783974*PED	Mar 01, 2008			
<u>ESTRADIOL - ELESTRIN</u>					
021813 001	>A> 7198801	Jun 25, 2022		DP	
<u>ESTRADIOL; NORETHINDRONE ACETATE - ACTIVELLA</u>					
020907 002				D-104 I-525	Dec 28, 2009 Dec 29, 2009
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>					
020992 001	5908638	Jul 26, 2015		DP	
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>					
021443 001				>A> I-528	Apr 23, 2010
<u>FENTANYL CITRATE - ACTIQ</u>					
020747 001				M-63	Feb 06, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ACTIQ</u>							
020747	002					M-63	Feb 06, 2010
<u>FENTANYL CITRATE - ACTIQ</u>							
020747	003					M-63	Feb 06, 2010
<u>FENTANYL CITRATE - ACTIQ</u>							
020747	004					M-63	Feb 06, 2010
<u>FENTANYL CITRATE - ACTIQ</u>							
020747	005					M-63	Feb 06, 2010
<u>FENTANYL CITRATE - ACTIQ</u>							
020747	006					M-63	Feb 06, 2010
<u>FENTANYL CITRATE - FENTORA</u>							
021947	006					NDF	Sep 25, 2009
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>							
021520	002	5229382	Apr 23, 2011	DS	DP	NC	Dec 24, 2006
		5229382*PED	Oct 23, 2011			PED	Jun 24, 2007
		5945416	Mar 24, 2017	DS	DP		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>							
021520	003	5229382	Apr 23, 2011	DS	DP	NC	Dec 24, 2006
		5229382*PED	Oct 23, 2011			PED	Jun 24, 2007
		5945416	Mar 24, 2017	DS	DP		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>							
021520	004	5229382	Apr 23, 2011	DS	DP	NC	Dec 24, 2006
		5229382*PED	Oct 23, 2011			PED	Jun 24, 2007
		5945416	Mar 24, 2017	DS	DP		
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>							
021520	005	5229382	Apr 23, 2011	DS	DP	NC	Dec 24, 2006
		5229382*PED	Oct 23, 2011			PED	Jun 24, 2007
		5945416	Mar 24, 2017	DS	DP		
<u>FORMOTEROL FUMARATE - FORADIL CERTIHALER</u>							
021592	001	6182655	Dec 05, 2016		DP	NP	Dec 15, 2009
		6645466	Nov 10, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>							
021615	001	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>							
021615	002	7160559	Dec 20, 2019		DP		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>							
021615	003	7160559	Dec 20, 2019		DP		
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>							
020818	004	5399578	Mar 21, 2012	DS	DP	U-3	
		6294197	Jun 18, 2017		DP	U-3	
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>							
020818	005	5399578	Mar 21, 2012	DS	DP	U-3	
		6294197	Jun 18, 2017		DP	U-3	
<u>HYDROXOCOBALAMIN - CYANOKIT</u>							
022041	002	5834448	Nov 14, 2016		DP	U-789	ODE
<u>IBANDRONATE SODIUM - BONIVA</u>							
021455	001	4927814	Jul 09, 2008	DS	DP	U-700	
		4927814	Jul 09, 2008	DS	DP	U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>							
021455	002	4927814	Jul 09, 2008	DS	DP	U-700	
		4927814	Jul 09, 2008	DS	DP	U-642	
		7192938	May 06, 2023			U-798	
<u>IBUPROFEN LYSINE - NEOPROFEN</u>							
021903	001	6342530	Nov 14, 2020	DS	DP	U-794	
		6344479	Mar 20, 2021	DS	DP	U-794	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335 001	6958335	Dec 19, 2021	U-791		
	6958335*PED	Jun 19, 2022			
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021335 002	6958335	Dec 19, 2021	U-791		
	6958335*PED	Jun 19, 2022			
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588 001	6958335	Dec 19, 2021	U-791		
	6958335*PED	Jun 19, 2022			
<u>IMATINIB MESYLATE - GLEEVEC</u>					
021588 002	6958335	Dec 19, 2021	U-791		
	6958335*PED	Jun 19, 2022			
<u>IRON SUCROSE - VENOFER</u>					
021135 004				I-474 I-459	Oct 17, 2008 Jun 17, 2008
<u>KETOCONAZOLE - XOLEGEL</u>					
021946 001	7179475	Dec 04, 2018	DP U-792		
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 001	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 002	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 003	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 004	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 005	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL</u>					
020241 006	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
<u>LAMOTRIGINE - LAMICTAL CD</u>					
020764 001	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
<u>LAMOTRIGINE - LAMICTAL CD</u>					
020764 002	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
<u>LAMOTRIGINE - LAMICTAL CD</u>					
020764 003	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			
<u>LAMOTRIGINE - LAMICTAL CD</u>					
020764 004	4602017	Jul 22, 2008	U-106	I-516 PED	Sep 22, 2009 Mar 22, 2010
	4602017*PED	Jan 22, 2009			
	5698226	Jan 29, 2012			
	5698226*PED	Jul 29, 2012			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>					
022059 001	>A> 6391874	Jul 11, 2017	DS DP	U-800	NCE Mar 13, 2012
	>A> 6713485	Jan 08, 2019	DS DP	U-800	
	>A> 6727256	Jan 08, 2019	DS DP	U-800	
	>A> 6828320	Jul 11, 2017		U-800	
	>A> 7157466	Nov 19, 2021	DS DP		
<u>LATANOPROST - XALATAN</u>					
020597 001	7163959	Jun 19, 2010	DS		
<u>LENALIDOMIDE - REVLIMID</u>					
021880 001	7189740	Apr 11, 2023		U-769	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 002	7189740	Apr 11, 2023		U-769	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 003	7189740	Apr 11, 2023		U-769	
<u>LENALIDOMIDE - REVLIMID</u>					
021880 004	7189740	Apr 11, 2023		U-769	
<u>LEUPROLIDE ACETATE - ELIGARD</u>					
021343 001	>A> 6395293	Sep 28, 2013		DP U-801	
	>A> 6565874	Oct 28, 2018		DP U-801	
	>A> 6626870	Mar 27, 2020		DP	
	>A> 6773714	Oct 28, 2018		DP U-801	
	>A> RE37950	Oct 03, 2008		DP U-801	
<u>LEUPROLIDE ACETATE - ELIGARD</u>					
021379 001	>A> 6395293	Sep 28, 2013		DP	
	>A> 6565874	Oct 28, 2018		DP U-801	
	>A> 6626870	Mar 27, 2020		DP	
	>A> 6773714	Oct 28, 2018		DP U-801	
	>A> RE37950	Oct 03, 2008		DP U-801	
<u>LEUPROLIDE ACETATE - ELIGARD</u>					
021488 001	>A> 6395293	Sep 28, 2013		DP	
	>A> 6565874	Oct 28, 2018		DP U-801	
	>A> 6626870	Mar 27, 2020		DP	
	>A> 6773714	Oct 28, 2018		DP U-801	
	>A> RE37950	Oct 03, 2008		DP U-801	
<u>LEVETIRACETAM - KEPPRA</u>					
021035 001				>A> I-527	Mar 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>					
021035 002				>A> I-527	Mar 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>					
021035 003				>A> I-527	Mar 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>					
021035 004				>A> I-527	Mar 19, 2010
<u>LEVETIRACETAM - KEPPRA</u>					
021505 001				>A> I-527	Mar 19, 2010
<u>LEVOFLOXACIN - LEVAQUIN</u>					
020634 001	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83	Oct 23, 2006
				PED	Feb 04, 2009
				PED	Apr 23, 2007
<u>LEVOFLOXACIN - LEVAQUIN</u>					
020634 002	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83	Oct 23, 2006
				PED	Feb 04, 2009
				PED	Apr 23, 2007

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOFLOXACIN - LEVAQUIN</u>					
020634 003	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Apr 23, 2007 Feb 04, 2009
<u>LEVOFLOXACIN - LEVAQUIN</u>					
020635 001	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	>A> 5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Feb 04, 2009 Apr 23, 2007
<u>LEVOFLOXACIN - LEVAQUIN</u>					
020635 004	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Apr 23, 2007 Feb 04, 2009
<u>LEVOFLOXACIN - LEVAQUIN</u>					
021721 001	5053407	Dec 20, 2010	DS	U-36	Aug 04, 2008
	5053407*PED	Jun 20, 2011		PED	Feb 04, 2009
	6806256	Feb 26, 2022	DP		
	6806256*PED	Aug 26, 2022			
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
020635 002	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Feb 04, 2009 Apr 23, 2007
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
020635 003	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Feb 04, 2009 Apr 23, 2007
<u>LEVOFLOXACIN - LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
020635 005	5053407	Dec 20, 2010		D-100	Aug 04, 2008
	5053407*PED	Jun 20, 2011		D-83 PED PED	Oct 23, 2006 Apr 23, 2007 Feb 04, 2009
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>					
021977 001	7105486	Jun 29, 2023		U-727	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>					
021977 002	7105486	Jun 29, 2023		U-727	Feb 23, 2012
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>					
021977 003	7105486	Jun 29, 2023		U-727	Feb 23, 2012
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>					
020448 001	5489436	Feb 06, 2013	DP		
	6814978	Aug 26, 2021	DP		
<u>LOPINAVIR; RITONAVIR - KALETRA</u>					
021251 001	5914332	Dec 13, 2015		U-351	
<u>LOPINAVIR; RITONAVIR - KALETRA</u>					
021906 001	7148359	Jul 19, 2019	DP		
<u>MESALAMINE - LIALDA</u>					
022000 001	6773720	Jun 08, 2020	DP	NP	Jan 16, 2010
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 001				M-62	Jan 31, 2010
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 002				M-62	Jan 31, 2010
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 003				M-62	Jan 31, 2010
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 004				M-62	Jan 31, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 005				M-62	Jan 31, 2010
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>					
022044 001	>A> 6303661	Apr 24, 2017	U-802	>A> NC	Mar 30, 2010
	>A> 6699871	Jul 26, 2022 DS DP	U-802	>A> NCE	Oct 16, 2011
	>A> 6890898	Feb 02, 2019	U-803		
	>A> 7078381	Feb 02, 2019	U-803		
	>A> 7125873	Jul 26, 2022 DP	U-803		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>					
022044 002	>A> 6303661	Apr 24, 2017	U-802	>A> NC	Mar 30, 2010
	>A> 6699871	Jul 26, 2022 DS DP	U-802	>A> NCE	Oct 16, 2011
	>A> 6890898	Feb 02, 2019	U-803		
	>A> 7078381	Feb 02, 2019	U-803		
	>A> 7125873	Jul 26, 2022 DP	U-803		
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>					
021415 001	>A> 6034267	Mar 08, 2016	U-804		
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>					
021026 001	4911932	Mar 27, 2008	DP	U-718	
<u>MONTELUKAST SODIUM - SINGULAIR</u>					
020829 002				>A> I-530	Apr 13, 2010
<u>MONTELUKAST SODIUM - SINGULAIR</u>					
020830 001				>A> I-530	Apr 13, 2010
<u>MONTELUKAST SODIUM - SINGULAIR</u>					
020830 002				>A> I-530	Apr 13, 2010
<u>MONTELUKAST SODIUM - SINGULAIR</u>					
021409 001				>A> I-530	Apr 13, 2010
<u>MORPHINE SULFATE - KADIAN</u>					
020616 006	>A> 5202128	Apr 13, 2010	DP		
	>A> 5378474	Mar 23, 2010	DP		
<u>MORPHINE SULFATE - KADIAN</u>					
020616 007	>A> 5202128	Apr 13, 2010	DP		
	>A> 5378474	Mar 23, 2010	DP		
<u>MORPHINE SULFATE - KADIAN</u>					
020616 008	>A> 5202128	Apr 13, 2010			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>					
021598 001	6716830	Sep 29, 2019	DP		
<u>OLANZAPINE - ZYPREXA</u>					
020592 001	5229382	Apr 23, 2011 DS DP	U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011 DS DP	U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			
<u>OLANZAPINE - ZYPREXA</u>					
020592 002	5229382	Apr 23, 2011 DS DP	U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011 DS DP	U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			
<u>OLANZAPINE - ZYPREXA</u>					
020592 003	5229382	Apr 23, 2011 DS DP	U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011 DS DP	U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			
<u>OLANZAPINE - ZYPREXA</u>					
020592 004	5229382	Apr 23, 2011 DS DP	U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011 DS DP	U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			
<u>OLANZAPINE - ZYPREXA</u>					
020592 005	5229382	Apr 23, 2011 DS DP	U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011 DS DP	U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE - ZYPREXA</u>					
020592 006	5229382	Apr 23, 2011	DS DP U-547	I-417	Jan 14, 2007
	5229382	Apr 23, 2011	DS DP U-149	PED	Jul 14, 2007
	5229382*PED	Oct 23, 2011			
<u>OLANZAPINE - ZYPREXA</u>					
021253 001	5229382	Apr 23, 2011	DS DP U-571	NP	Mar 29, 2007
	5229382*PED	Oct 23, 2011		NDF	Mar 29, 2007
				PED	Sep 29, 2007
				PED	Sep 29, 2007
<u>OLANZAPINE - ZYPREXA ZYDIS</u>					
021086 001	5229382	Apr 23, 2011		U-324	I-400
	5229382*PED	Oct 23, 2011			I-417
					PED
					PED
<u>OLANZAPINE - ZYPREXA ZYDIS</u>					
021086 002	5229382	Apr 23, 2011		U-324	I-400
	5229382*PED	Oct 23, 2011			I-417
					PED
					PED
<u>OLANZAPINE - ZYPREXA ZYDIS</u>					
021086 003	5229382	Apr 23, 2011		U-324	I-400
	5229382*PED	Oct 23, 2011			I-417
					PED
					PED
<u>OLANZAPINE - ZYPREXA ZYDIS</u>					
021086 004	5229382	Apr 23, 2011		U-324	I-400
	5229382*PED	Oct 23, 2011			I-417
					PED
					PED
<u>ONDANSETRON - ONDANSETRON</u>					
076506 001					PC
<u>ONDANSETRON - ONDANSETRON</u>					
076506 002					PC
<u>ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE</u>					
076183 001					PC
<u>ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE</u>					
076183 002					PC
<u>ONDANSETRON HYDROCHLORIDE - ONDANSETRON HYDROCHLORIDE</u>					
076183 003					PC
<u>ORLISTAT - ALLI</u>					
021887 001	4598089	Jun 18, 2009	DS DP		NP
	6004996	Jan 06, 2018			DP
<u>OXALIPLATIN - ELOXATIN</u>					
021492 001					M-61
					PED
<u>OXALIPLATIN - ELOXATIN</u>					
021492 002					M-61
					PED
<u>OXALIPLATIN - ELOXATIN</u>					
021759 001	5420319	Aug 09, 2016	DS		
	5420319*PED	Feb 09, 2017			
<u>OXALIPLATIN - ELOXATIN</u>					
021759 002	5420319	Aug 09, 2016	DS		
	5420319*PED	Feb 09, 2017			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>					
021759 003	5290961	Jan 12, 2013	DS		
	5290961*PED	Jul 12, 2013			
	5338874	Apr 07, 2013	DS		
	5338874*PED	Oct 07, 2013			
	5420319	Aug 09, 2016	DS		
	5420319*PED	Feb 09, 2017			
	5716988	Aug 07, 2015		DP	
	5716988*PED	Feb 07, 2016			
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 001	7037525	Feb 12, 2018		U-724	
	7037525*PED	Aug 12, 2018			
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 002	7037525	Feb 12, 2018		U-724	
	7037525*PED	Aug 12, 2018			
<u>OXCARBAZEPINE - TRILEPTAL</u>					
021014 003	7037525	Feb 12, 2018		U-724	
	7037525*PED	Aug 12, 2018			
<u>OXYBUTYNIN - OXYTROL</u>					
021351 002	7179483	Apr 26, 2020	DS DP	U-318	
<u>PALIPERIDONE - INVEGA</u>					
021999 001	5158952	Oct 27, 2009		DP U-90	
<u>PALIPERIDONE - INVEGA</u>					
021999 002	5158952	Oct 27, 2009		DP U-90	
<u>PALIPERIDONE - INVEGA</u>					
021999 003	5158952	Oct 27, 2009		DP U-90	
<u>PALIPERIDONE - INVEGA</u>					
021999 004	5158952	Oct 27, 2009		DP U-90	
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>					
077395 001				PC	Jun 10, 2007
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>					
020936 001	5789449	Jan 06, 2009		U-788	
	5789449*PED	Jul 06, 2009			
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>					
020936 002	5789449	Jan 06, 2009		U-788	
	5789449*PED	Jul 06, 2009			
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>					
020936 003	5789449	Jan 06, 2009		U-788	
	5789449*PED	Jul 06, 2009			
<u>PEMETREXED DISODIUM - ALIMTA</u>					
021462 001	>A> 5344932	Jul 24, 2016	DS DP		
<u>RAMIPRIL - ALTACE</u>					
019901 001	>A> 5061722	Oct 29, 2008			
<u>RAMIPRIL - ALTACE</u>					
019901 002	>A> 5061722	Oct 29, 2008			
<u>RAMIPRIL - ALTACE</u>					
019901 003	>A> 5061722	Oct 29, 2008			
<u>RAMIPRIL - ALTACE</u>					
019901 004	>A> 5061722	Oct 29, 2008			
<u>RAMIPRIL - ALTACE</u>					
022021 001	>A> 5061722	Oct 29, 2008	DS DP	U-185	
	>A> 5403856	Apr 04, 2012		U-71	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RAMIPRIL - ALTACE</u>					
022021 002	>A> 5061722	Oct 29, 2008	DS DP	U-185	
	>A> 5403856	Apr 04, 2012		U-71	
<u>RAMIPRIL - ALTACE</u>					
022021 003	>A> 5061722	Oct 29, 2008	DS DP	U-185	
	>A> 5403856	Apr 04, 2012		U-71	
<u>RAMIPRIL - ALTACE</u>					
022021 004	>A> 5061722	Oct 29, 2008	DS DP	U-185	
	>A> 5403856	Apr 04, 2012		U-71	
<u>RANITIDINE HYDROCHLORIDE - RANITIDINE HYDROCHLORIDE</u>					
076124 001				PC	Sep 15, 2007
<u>RETAPAMULIN - ALTABAX</u>					
022055 001				>A> NCE	Apr 12, 2012
<u>RISEDRONATE SODIUM - ACTONEL</u>					
020835 004				>A> D-105	Apr 16, 2010
				>A> M-52	Jan 24, 2009
<u>RISPERIDONE - RISPERDAL</u>					
020272 001	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>					
020272 002	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>					
020272 003	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>					
020272 004	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>					
020272 005	4804663	Dec 29, 2007		U-90	I-413 Dec 04, 2006
	4804663*PED	Jun 29, 2008			I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
<u>RISPERIDONE - RISPERDAL</u>					
020272 007	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>					
020272 008	4804663	Dec 29, 2007		U-90	I-509 Oct 06, 2009
	4804663*PED	Jun 29, 2008			I-413 Dec 04, 2006
					I-412 Dec 04, 2006
					PED Jun 04, 2007
					PED Jun 04, 2007
					PED Apr 06, 2010

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL</u>							
020588 001	4804663	Dec 29, 2007			U-90	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008				I-413	Dec 04, 2006
	5453425	Jul 11, 2014				I-412	Dec 04, 2006
	5453425*PED	Jan 11, 2015				PED	Apr 06, 2010
	5616587	Jul 11, 2014				PED	Jun 04, 2007
	5616587*PED	Jan 11, 2015				PED	Jun 04, 2007
	RE39181	Jul 11, 2014		DP			
	RE39181*PED	Jan 11, 2015					
<u>RISPERIDONE - RISPERDAL</u>							
021444 001	4804663	Dec 29, 2007	DS	DP	U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008				I-413	Dec 04, 2006
	5648093	Jul 15, 2014		DP		I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015				PED	Jun 04, 2007
	6224905	Jun 10, 2017		DP		PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017				PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>							
021444 002	4804663	Dec 29, 2007	DS	DP	U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008				I-413	Dec 04, 2006
	5648093	Jul 15, 2014		DP		I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015				PED	Jun 04, 2007
	6224905	Jun 10, 2017		DP		PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017				PED	Apr 06, 2010
<u>RISPERIDONE - RISPERDAL</u>							
021444 003	4804663	Dec 29, 2007	DS	DP	U-516	I-509	Oct 06, 2009
	4804663*PED	Jun 29, 2008				I-413	Dec 04, 2006
	5648093	Jul 15, 2014		DP		I-412	Dec 04, 2006
	5648093*PED	Jan 15, 2015				PED	Apr 06, 2010
	6224905	Jun 10, 2017		DP		PED	Jun 04, 2007
	6244905*PED	Dec 10, 2017				PED	Jun 04, 2007
<u>RISPERIDONE - RISPERDAL</u>							
021444 004	4804663	Dec 29, 2007	DS	DP	U-516	I-509	Oct 06, 2009
	4804663	Dec 29, 2007	DS	DP	U-543	I-413	Dec 04, 2006
	4804663*PED	Jun 29, 2008				I-412	Dec 04, 2006
	5648093	Jul 15, 2014		DP		PED	Jun 04, 2007
	5648093*PED	Jan 15, 2015				PED	Jun 04, 2007
	6224905	Jun 10, 2017		DP		PED	Apr 06, 2010
	6244905*PED	Dec 10, 2017					
<u>RISPERIDONE - RISPERDAL</u>							
021444 005	4804663	Dec 29, 2007	DS	DP	U-516	I-509	Oct 06, 2009
	4804663	Dec 29, 2007	DS	DP	U-543	I-413	Dec 04, 2006
	4804663*PED	Jun 29, 2008				I-412	Dec 04, 2006
	5648093	Jul 15, 2014		DP		PED	Jun 04, 2007
	5648093*PED	Jan 15, 2015				PED	Jun 04, 2007
	6224905	Jun 10, 2017		DP		PED	Apr 06, 2010
	6244905*PED	Dec 10, 2017					

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>					
021346 001	4804663	Dec 29, 2007		NDF	Oct 29, 2006
	4804663*PED	Jun 29, 2008		PED	Apr 29, 2007
	5688801	Nov 18, 2014			
	5688801*PED	May 18, 2015			
	5770231	Nov 19, 2013			
	5770231*PED	May 19, 2014			
	5792477	May 02, 2017			
	5792477*PED	Nov 02, 2017			
	5916598	May 02, 2017			
	5916598*PED	Nov 02, 2017			
	5965168	Nov 19, 2013			
	5965168*PED	May 19, 2014			
	6110503	May 02, 2017			
	6110503*PED	Nov 02, 2017			
	6110921	Nov 19, 2013			
	6110921*PED	May 19, 2014			
	6194006	Dec 30, 2018			
	6194006*PED	Jun 30, 2019			
	6264987	May 19, 2020			
	6264987*PED	Nov 19, 2020			
	6368632	Nov 19, 2013		U-543	
	6368632*PED	May 19, 2014			
	6379703	Dec 30, 2018	DP		
	6379703*PED	Jun 30, 2019			
	6379704	May 19, 2020	DP		
	6379704*PED	Nov 19, 2020			
	6403114	May 02, 2017			
	6403114*PED	Nov 02, 2017			
	6534092	May 19, 2020	DP		
	6534092*PED	Nov 19, 2020			
	6596316	Dec 30, 2008	DP		
	6596316*PED	Jun 30, 2009			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>					
021346 002	4804663	Dec 29, 2007		NDF	Oct 29, 2006
	4804663*PED	Jun 29, 2008		PED	Apr 29, 2007
	5688801	Nov 18, 2014			
	5688801*PED	May 18, 2015			
	5770231	Nov 19, 2013			
	5770231*PED	May 19, 2014			
	5792477	May 02, 2017			
	5792477*PED	Nov 02, 2017			
	5916598	May 02, 2017			
	5916598*PED	Nov 02, 2017			
	5965168	Nov 19, 2013			
	5965168*PED	May 19, 2014			
	6110503	May 02, 2017			
	6110503*PED	Nov 02, 2017			
	6110921	Nov 19, 2013			
	6110921*PED	May 19, 2014			
	6194006	Dec 30, 2018			
	6194006*PED	Jun 30, 2019			
	6264987	May 19, 2020			
	6264987*PED	Nov 19, 2020			
	6368632	Nov 19, 2013		U-543	
	6368632*PED	May 19, 2014			
	6379703	Dec 30, 2018	DP		
	6379703*PED	Jun 30, 2019			
	6379704	May 19, 2020	DP		
	6379704*PED	Nov 19, 2020			
	6403114	May 02, 2017			
	6403114*PED	Nov 02, 2017			
	6534092	May 19, 2020	DP		
	6534092*PED	Nov 19, 2020			
	6596316	Dec 30, 2008	DP		
	6596316*PED	Jun 30, 2009			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>					
021346 003	4804663	Dec 29, 2007		NDF	Oct 29, 2006
	4804663*PED	Jun 29, 2008		PED	Apr 29, 2007
	5688801	Nov 18, 2014			
	5688801*PED	May 18, 2015			
	5770231	Nov 19, 2013			
	5770231*PED	May 19, 2014			
	5792477	May 02, 2017			
	5792477*PED	Nov 02, 2017			
	5916598	May 02, 2017			
	5916598*PED	Nov 02, 2017			
	5965168	Nov 19, 2013			
	5965168*PED	May 19, 2014			
	6110503	May 02, 2017			
	6110503*PED	Nov 02, 2017			
	6110921	Nov 19, 2013			
	6110921*PED	May 19, 2014			
	6194006	Dec 30, 2018			
	6194006*PED	Jun 30, 2019			
	6264987	May 19, 2020			
	6264987*PED	Nov 19, 2020			
	6368632	Nov 19, 2013		U-543	
	6368632*PED	May 19, 2014			
	6379703	Dec 30, 2018	DP		
	6379703*PED	Jun 30, 2019			
	6379704	May 19, 2020	DP		
	6379704*PED	Nov 19, 2020			
	6403114	May 02, 2017			
	6403114*PED	Nov 02, 2017			
	6534092	May 19, 2020	DP		
	6534092*PED	Nov 19, 2020			
	6596316	Dec 30, 2008	DP		
	6596316*PED	Jun 30, 2009			
<u>SELEGILINE - EMSAM</u>					
021336 001	7150881	Jun 12, 2018	DS DP		
<u>SELEGILINE - EMSAM</u>					
021336 002	7150881	Jun 12, 2018	DS DP		
<u>SELEGILINE - EMSAM</u>					
021336 003	7150881	Jun 12, 2018	DS DP		
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>					
019764 005				I-440	Aug 26, 2007
<u>TADALAFIL - CIALIS</u>					
021368 001	>A> 5859006	Nov 21, 2017	DS DP		
	7182958	Apr 26, 2020	DP	U-155	
<u>TADALAFIL - CIALIS</u>					
021368 002	>A> 5859006	Nov 21, 2017	DS DP		
	7182958	Apr 26, 2020	DP	U-155	
<u>TADALAFIL - CIALIS</u>					
021368 003	>A> 5859006	Nov 21, 2017	DS DP		
	7182958	Apr 26, 2020	DP	U-155	
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	7163684	Aug 19, 2019		U-790	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>					
020785 004	5629327	May 13, 2014	U-731	ODE	May 23, 2013
	6045501	Aug 28, 2018	U-731		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561977	Oct 23, 2020	U-731		
	6755784	Oct 23, 2020	U-731		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-731		
	7141018	Oct 23, 2020	U-731		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>					
020963 001	6174524	Mar 26, 2019			
	6174524*PED	Sep 26, 2019			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>					
020963 002	6174524	Mar 26, 2019			
	6174524*PED	Sep 26, 2019			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>					
021483 001	7175855	May 18, 2020	DP		
<u>ZOLEDRONIC ACID - RECLAST</u>					
021817 001				>A> NP	Apr 16, 2010
<u>ZOLPIDEM TARTRATE - AMBIEN</u>					
019908 001				M-54 PED	Mar 29, 2010 Sep 29, 2010
<u>ZOLPIDEM TARTRATE - AMBIEN</u>					
019908 002				M-54 PED	Mar 29, 2010 Sep 29, 2010

Footnotes:

- Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
- Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
- Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
- *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
- *** U.S. Patent Nos. RE 36481 and RE 36520 were relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v. Leavitt*, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents remained listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act were triggered and run. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046. Patents were subsequently delisted in the December 2006 Orange Book update as the exclusivity periods have triggered and run to expiration.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 27th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>